



Belgian Cancer Registry

## CANCER FACT SHEET 2022

### THYROID CANCER

ICD-10 C73



## CONCEPTS AND ABBREVIATIONS

**Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

**Average Annual Percentage Change (AAPC):** The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ( $=200 \times 1.05$ ) and 255/100,000 over 5 years ( $=200 \times (1.05)^5$ ).

**Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

**ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

**Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

**Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8<sup>th</sup> edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

**95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



|                                                                                                                                                                                                          |    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1. CANCER INCIDENCE .....                                                                                                                                                                                | 5  |
| 1.1. Thyroid cancer incidence: by region .....                                                                                                                                                           | 5  |
| 1.1.1. Thyroid cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....                                                          | 5  |
| 1.2. Thyroid cancer incidence: by tumour stage.....                                                                                                                                                      | 7  |
| 1.2.1. Thyroid cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....                                            | 7  |
| 1.2.2. Thyroid cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....                                       | 7  |
| 1.2.3. Thyroid cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....                                                              | 8  |
| 1.3. Thyroid cancer incidence: by tumour type.....                                                                                                                                                       | 9  |
| 1.3.1. Thyroid cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....                                                               | 9  |
| 1.4. Thyroid cancer incidence: by tumour type and tumour stage .....                                                                                                                                     | 10 |
| 1.4.1. Thyroid cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....                                                        | 10 |
| 2. CANCER INCIDENCE TRENDS .....                                                                                                                                                                         | 12 |
| 2.1. Thyroid cancer incidence trends: by region .....                                                                                                                                                    | 12 |
| 2.1.1. Thyroid cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....              | 12 |
| 2.1.2. Thyroid cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....            | 14 |
| 2.2. Thyroid cancer incidence trends: by tumour stage .....                                                                                                                                              | 15 |
| 2.2.1. Thyroid cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards... | 15 |
| 2.3. Thyroid cancer incidence trends: by tumour type .....                                                                                                                                               | 17 |
| 2.3.1. Thyroid cancer incidence trends in males by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022 .....                | 17 |
| 2.3.2. Thyroid cancer incidence trends in females by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....               | 18 |
| 2.4. Thyroid cancer incidence trends: by age group .....                                                                                                                                                 | 19 |
| 2.4.1. Thyroid cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....           | 19 |
| 2.4.2. Thyroid cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....         | 20 |
| 3. CANCER PREVALENCE .....                                                                                                                                                                               | 21 |
| 3.1. Thyroid cancer prevalence: by region .....                                                                                                                                                          | 21 |
| 3.1.1. Thyroid cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022.....                                                            | 21 |
| 4. CANCER SURVIVAL.....                                                                                                                                                                                  | 22 |

|                                                                                                                                                                                                 |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 4.1. Thyroid cancer survival: by region.....                                                                                                                                                    | 22 |
| 4.1.1. Thyroid cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022 .....                                                                     | 22 |
| 4.2. Thyroid cancer survival: by tumour type and tumour stage .....                                                                                                                             | 24 |
| 4.2.1. Thyroid cancer survival by type, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022 .....                                                         | 24 |
| 4.2.2. Thyroid cancer survival by type, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2013-2022 .....                                                     | 28 |
| 4.2.3. Thyroid cancer survival by type, stage and sex: number at risk and net survival probabilities, 2013-2022 .....                                                                           | 32 |
| 5. CANCER SURVIVAL TRENDS.....                                                                                                                                                                  | 36 |
| 5.1. Thyroid cancer survival trends: by tumour type and tumour stage.....                                                                                                                       | 36 |
| 5.1.1. Thyroid cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2008-2022 .....                                                                    | 36 |
| 6. CANCER MORTALITY .....                                                                                                                                                                       | 42 |
| 6.1. Thyroid cancer mortality: by region.....                                                                                                                                                   | 42 |
| 6.1.1. Thyroid cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021 .....                                               | 42 |
| 7. CANCER MORTALITY TRENDS.....                                                                                                                                                                 | 44 |
| 7.1. Thyroid cancer mortality trends: by region .....                                                                                                                                           | 44 |
| 7.1.1. Thyroid cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....   | 44 |
| 7.1.2. Thyroid cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 ..... | 45 |



# 1. CANCER INCIDENCE



## 1.1. Thyroid cancer incidence: by region

1.1.1. Thyroid cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022

| Region         | N [CR] |       |       |       |       |       |        |        |        |        |        |        |        |        |        |        |        |        |        |       | All ages | ESR2013 (95%CI) |  |
|----------------|--------|-------|-------|-------|-------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|----------|-----------------|--|
|                | 0-     | 5-    | 10-   | 15-   | 20-   | 25-   | 30-    | 35-    | 40-    | 45-    | 50-    | 55-    | 60-    | 65-    | 70-    | 75-    | 80-    | 85-    | 90-    | 95-   |          |                 |  |
| Males          |        |       |       |       |       |       |        |        |        |        |        |        |        |        |        |        |        |        |        |       |          |                 |  |
| <b>Belgium</b> | 0      | 0     | 1     | 0     | 4     | 9     | 11     | 19     | 19     | 24     | 20     | 32     | 56     | 33     | 32     | 24     | 7      | 10     | 2      | 0     | 303      | 5.4             |  |
|                | [0.0]  | [0.0] | [0.3] | [0.0] | [1.2] | [2.5] | [2.9]  | [5.1]  | [5.0]  | [6.4]  | [5.0]  | [7.9]  | [15.2] | [10.6] | [12.1] | [12.6] | [5.5]  | [12.7] | [6.7]  | [0.0] | [5.3]    | (4.8; 6.0)      |  |
| Brussels       | 0      | 0     | 0     | 0     | 0     | 1     | 1      | 3      | 1      | 1      | 4      | 0      | 4      | 4      | 3      | 0      | 0      | 0      | 0      | 0     | 22       | 4.5             |  |
|                | [0.0]  | [0.0] | [0.0] | [0.0] | [0.0] | [2.0] | [1.9]  | [6.4]  | [2.2]  | [2.3]  | [9.9]  | [0.0]  | [14.3] | [18.9] | [18.2] | [0.0]  | [0.0]  | [0.0]  | [0.0]  | [0.0] | [3.7]    | (2.5; 6.5)      |  |
| Flanders       | 0      | 0     | 1     | 0     | 3     | 4     | 6      | 9      | 10     | 10     | 12     | 18     | 25     | 12     | 16     | 21     | 4      | 7      | 0      | 0     | 158      | 4.7             |  |
|                | [0.0]  | [0.0] | [0.5] | [0.0] | [1.6] | [2.0] | [2.8]  | [4.3]  | [4.6]  | [4.7]  | [5.2]  | [7.4]  | [11.1] | [6.2]  | [9.9]  | [17.0] | [4.8]  | [13.3] | [0.0]  | [0.0] | [4.8]    | (4.0; 5.5)      |  |
| Wallonia       | 0      | 0     | 0     | 0     | 1     | 4     | 4      | 7      | 8      | 13     | 4      | 14     | 27     | 17     | 13     | 3      | 3      | 3      | 2      | 0     | 123      | 7.0             |  |
|                | [0.0]  | [0.0] | [0.0] | [0.0] | [0.9] | [3.6] | [3.4]  | [6.1]  | [6.9]  | [10.8] | [3.2]  | [11.2] | [23.2] | [17.1] | [15.1] | [5.5]  | [8.6]  | [14.4] | [25.2] | [0.0] | [6.9]    | (5.8; 8.3)      |  |
| Females        |        |       |       |       |       |       |        |        |        |        |        |        |        |        |        |        |        |        |        |       |          |                 |  |
| <b>Belgium</b> | 0      | 0     | 3     | 11    | 18    | 28    | 52     | 67     | 70     | 80     | 94     | 75     | 58     | 56     | 53     | 35     | 16     | 12     | 5      | 2     | 735      | 12.7            |  |
|                | [0.0]  | [0.0] | [0.9] | [3.5] | [5.4] | [7.8] | [13.6] | [18.0] | [18.5] | [21.8] | [24.3] | [18.8] | [15.4] | [16.8] | [18.0] | [15.1] | [9.0]  | [8.9]  | [7.2]  | [9.7] | [12.5]   | (11.8; 13.6)    |  |
| Brussels       | 0      | 0     | 1     | 0     | 2     | 3     | 7      | 10     | 9      | 10     | 11     | 10     | 11     | 11     | 3      | 2      | 2      | 1      | 1      | 0     | 94       | 16.7            |  |
|                | [0.0]  | [0.0] | [2.7] | [0.0] | [5.0] | [5.5] | [13.2] | [21.1] | [20.0] | [24.8] | [29.5] | [29.6] | [37.0] | [44.2] | [14.1] | [11.6] | [15.4] | [9.9]  | [17.3] | [0.0] | [15.1]   | (13.3; 20.2)    |  |

| Region   | N [CR] |       |       |       |       |       |        |        |        |        |        |        |        |        |        |        |       |       |       |        | All ages | ESR2013 (95%CI) |
|----------|--------|-------|-------|-------|-------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|-------|-------|--------|----------|-----------------|
|          | 0-     | 5-    | 10-   | 15-   | 20-   | 25-   | 30-    | 35-    | 40-    | 45-    | 50-    | 55-    | 60-    | 65-    | 70-    | 75-    | 80-   | 85-   | 90-   | 95-    |          |                 |
| Flanders | 0      | 0     | 1     | 8     | 7     | 15    | 21     | 36     | 33     | 37     | 50     | 42     | 23     | 26     | 27     | 20     | 11    | 8     | 3     | 2      | 370      | 11.0            |
|          | [0.0]  | [0.0] | [0.5] | [4.6] | [3.9] | [7.6] | [9.9]  | [17.1] | [15.2] | [17.9] | [22.2] | [17.6] | [10.2] | [13.1] | [15.6] | [14.0] | [9.8] | [9.4] | [7.0] | [16.6] | [10.9]   | (9.9; 12.1)     |
| Wallonia | 0      | 0     | 1     | 3     | 9     | 10    | 24     | 21     | 28     | 33     | 33     | 23     | 24     | 19     | 23     | 13     | 3     | 3     | 1     | 0      | 271      | 14.8            |
|          | [0.0]  | [0.0] | [0.9] | [2.8] | [8.2] | [9.3] | [20.2] | [18.1] | [24.1] | [27.5] | [26.5] | [18.1] | [19.6] | [17.3] | [22.9] | [18.3] | [5.6] | [7.6] | [4.8] | [0.0]  | [14.5]   | (13.0; 16.5)    |

## 1.2. Thyroid cancer incidence: by tumour stage

1.2.1. Thyroid cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

| cStage | Males    |          |          |           |                 | Females   |           |          |           |                 |
|--------|----------|----------|----------|-----------|-----------------|-----------|-----------|----------|-----------|-----------------|
|        | N[CR]    |          |          |           | ESR2013 (95%CI) | N[CR]     |           |          |           | ESR2013 (95%CI) |
|        | 15-54    | 55-74    | 75+      | All ages  |                 | 15-54     | 55-74     | 75+      | All ages  |                 |
| I      | 61 [2.1] | 65 [4.8] | 13 [3.0] | 140 [2.5] | 2.5 (2.1; 2.9)  | 284 [9.8] | 100 [7.1] | 21 [3.3] | 407 [6.9] | 7.2 (6.5; 7.9)  |
| II     | 2 [0.1]  | 15 [1.1] | 6 [1.4]  | 23 [0.4]  | 0.4 (0.2; 0.6)  | 1 [0.0]   | 20 [1.4]  | 10 [1.6] | 31 [0.5]  | 0.5 (0.3; 0.7)  |
| III    | 1 [0.0]  | 3 [0.2]  | 2 [0.5]  | 6 [0.1]   | 0.1 (0.0; 0.2)  | 0 [0.0]   | 2 [0.1]   | 3 [0.5]  | 5 [0.1]   | 0.1 (0.0; 0.1)  |
| IV     | 3 [0.1]  | 14 [1.0] | 13 [3.0] | 30 [0.5]  | 0.6 (0.4; 0.8)  | 2 [0.1]   | 15 [1.1]  | 16 [2.5] | 34 [0.6]  | 0.5 (0.3; 0.7)  |
| X/NA   | 39 [1.3] | 56 [4.1] | 9 [2.1]  | 104 [1.8] | 1.8 (1.5; 2.2)  | 133 [4.6] | 105 [7.5] | 20 [3.2] | 258 [4.4] | 4.4 (3.9; 5.0)  |

1.2.2. Thyroid cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

| pStage | Males    |          |          |           |                 | Females    |            |          |            |                  |
|--------|----------|----------|----------|-----------|-----------------|------------|------------|----------|------------|------------------|
|        | N[CR]    |          |          |           | ESR2013 (95%CI) | N[CR]      |            |          |            | ESR2013 (95%CI)  |
|        | 15-54    | 55-74    | 75+      | All ages  |                 | 15-54      | 55-74      | 75+      | All ages   |                  |
| I      | 91 [3.1] | 98 [7.3] | 12 [2.8] | 202 [3.5] | 3.6 (3.1; 4.1)  | 396 [13.7] | 170 [12.1] | 28 [4.4] | 596 [10.1] | 10.5 (9.6; 11.3) |
| II     | 2 [0.1]  | 27 [2.0] | 9 [2.1]  | 38 [0.7]  | 0.7 (0.5; 0.9)  | 2 [0.1]    | 41 [2.9]   | 9 [1.4]  | 52 [0.9]   | 0.8 (0.6; 1.1)   |
| III    | 1 [0.0]  | 5 [0.4]  | 0 [0.0]  | 6 [0.1]   | 0.1 (0.0; 0.2)  | 0 [0.0]    | 3 [0.2]    | 6 [0.9]  | 9 [0.2]    | 0.1 (0.0; 0.2)   |
| IV     | 3 [0.1]  | 8 [0.6]  | 7 [1.6]  | 18 [0.3]  | 0.3 (0.2; 0.5)  | 2 [0.1]    | 10 [0.7]   | 13 [2.1] | 26 [0.4]   | 0.4 (0.3; 0.6)   |
| X/NA   | 9 [0.3]  | 15 [1.1] | 15 [3.5] | 39 [0.7]  | 0.7 (0.5; 1.0)  | 20 [0.7]   | 18 [1.3]   | 14 [2.2] | 52 [0.9]   | 0.8 (0.6; 1.1)   |

1.2.3. Thyroid cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

| Stage       | Males    |           |          |           |                 | Females    |            |          |            |                  |
|-------------|----------|-----------|----------|-----------|-----------------|------------|------------|----------|------------|------------------|
|             | N[CR]    |           |          |           | ESR2013 (95%CI) | N[CR]      |            |          |            | ESR2013 (95%CI)  |
|             | 15-54    | 55-74     | 75+      | All ages  |                 | 15-54      | 55-74      | 75+      | All ages   |                  |
| <b>I</b>    | 93 [3.2] | 102 [7.6] | 15 [3.5] | 211 [3.7] | 3.7 (3.2; 4.3)  | 397 [13.7] | 172 [12.3] | 29 [4.6] | 600 [10.2] | 10.5 (9.7; 11.4) |
| <b>II</b>   | 3 [0.1]  | 28 [2.1]  | 9 [2.1]  | 40 [0.7]  | 0.7 (0.5; 0.9)  | 3 [0.1]    | 39 [2.8]   | 12 [1.9] | 54 [0.9]   | 0.9 (0.6; 1.1)   |
| <b>III</b>  | 1 [0.0]  | 3 [0.2]   | 2 [0.5]  | 6 [0.1]   | 0.1 (0.0; 0.2)  | 0 [0.0]    | 4 [0.3]    | 6 [0.9]  | 10 [0.2]   | 0.1 (0.1; 0.2)   |
| <b>IV</b>   | 3 [0.1]  | 14 [1.0]  | 13 [3.0] | 30 [0.5]  | 0.6 (0.4; 0.8)  | 2 [0.1]    | 17 [1.2]   | 17 [2.7] | 37 [0.6]   | 0.6 (0.4; 0.8)   |
| <b>X/NA</b> | 6 [0.2]  | 6 [0.4]   | 4 [0.9]  | 16 [0.3]  | 0.3 (0.1; 0.4)  | 18 [0.6]   | 10 [0.7]   | 6 [0.9]  | 34 [0.6]   | 0.6 (0.4; 0.8)   |



### 1.3. Thyroid cancer incidence: by tumour type

1.3.1. *Thyroid cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022*

| Type                                | Males    |           |          |           |                 | Females    |            |          |            |                  |
|-------------------------------------|----------|-----------|----------|-----------|-----------------|------------|------------|----------|------------|------------------|
|                                     | N[CR]    |           |          |           | ESR2013 (95%CI) | N[CR]      |            |          |            | ESR2013 (95%CI)  |
|                                     | 15-54    | 55-74     | 75+      | All ages  |                 | 15-54      | 55-74      | 75+      | All ages   |                  |
| <b>Papillary carcinoma</b>          | 82 [2.8] | 105 [7.8] | 16 [3.7] | 204 [3.6] | 3.6 (3.1; 4.1)  | 371 [12.8] | 187 [13.3] | 31 [4.9] | 591 [10.1] | 10.3 (9.5; 11.2) |
| <b>Papillary carcinoma &lt;55y</b>  | 82 [2.8] | 0 [0.0]   | 0 [0.0]  | 83 [1.5]  | 1.5 (1.2; 1.8)  | 371 [12.8] | 0 [0.0]    | 0 [0.0]  | 373 [6.3]  | 6.8 (6.1; 7.5)   |
| <b>Papillary carcinoma 55+y</b>     | 0 [0.0]  | 105 [7.8] | 16 [3.7] | 121 [2.1] | 2.1 (1.7; 2.5)  | 0 [0.0]    | 187 [13.3] | 31 [4.9] | 218 [3.7]  | 3.6 (3.1; 4.0)   |
| <b>Follicular carcinoma</b>         | 14 [0.5] | 28 [2.1]  | 10 [2.3] | 52 [0.9]  | 0.9 (0.7; 1.2)  | 37 [1.3]   | 28 [2.0]   | 18 [2.8] | 83 [1.4]   | 1.4 (1.1; 1.7)   |
| <b>Follicular carcinoma &lt;55y</b> | 14 [0.5] | 0 [0.0]   | 0 [0.0]  | 14 [0.2]  | 0.3 (0.1; 0.4)  | 37 [1.3]   | 0 [0.0]    | 0 [0.0]  | 37 [0.6]   | 0.7 (0.5; 0.9)   |
| <b>Follicular carcinoma 55+y</b>    | 0 [0.0]  | 28 [2.1]  | 10 [2.3] | 38 [0.7]  | 0.7 (0.5; 0.9)  | 0 [0.0]    | 28 [2.0]   | 18 [2.8] | 46 [0.8]   | 0.7 (0.5; 0.9)   |
| <b>Medullary carcinoma</b>          | 5 [0.2]  | 5 [0.4]   | 3 [0.7]  | 13 [0.2]  | 0.2 (0.1; 0.4)  | 6 [0.2]    | 11 [0.8]   | 4 [0.6]  | 22 [0.4]   | 0.4 (0.2; 0.5)   |
| <b>Anaplastic carcinoma</b>         | 2 [0.1]  | 5 [0.4]   | 7 [1.6]  | 14 [0.2]  | 0.3 (0.1; 0.4)  | 0 [0.0]    | 4 [0.3]    | 8 [1.3]  | 12 [0.2]   | 0.2 (0.1; 0.3)   |
| <b>Other</b>                        | 3 [0.1]  | 10 [0.7]  | 7 [1.6]  | 20 [0.4]  | 0.4 (0.2; 0.5)  | 6 [0.2]    | 12 [0.9]   | 9 [1.4]  | 27 [0.5]   | 0.4 (0.3; 0.6)   |

## 1.4. Thyroid cancer incidence: by tumour type and tumour stage

1.4.1. Thyroid cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

| Type                      | Stage | Males    |          |                 |          |                | Females    |            |                 |           |                |
|---------------------------|-------|----------|----------|-----------------|----------|----------------|------------|------------|-----------------|-----------|----------------|
|                           |       | N[CR]    |          | ESR2013 (95%CI) |          |                | N[CR]      |            | ESR2013 (95%CI) |           |                |
|                           |       | 15-54    | 55-74    | 75+             | All ages | 15-54          | 55-74      | 75+        | All ages        |           |                |
| Papillary carcinoma <55y  | I     | 79 [2.7] | 0 [0.0]  | 0 [0.0]         | 80 [1.4] | 1.4 (1.1; 1.8) | 358 [12.4] | 0 [0.0]    | 0 [0.0]         | 360 [6.1] | 6.6 (5.9; 7.2) |
|                           | II    | 1 [0.0]  | 0 [0.0]  | 0 [0.0]         | 1 [0.0]  | 0.0 (0.0; 0.1) | 1 [0.0]    | 0 [0.0]    | 0 [0.0]         | 1 [0.0]   | 0.0 (0.0; 0.1) |
|                           | III   | 0 [0.0]  | 0 [0.0]  | 0 [0.0]         | 0 [0.0]  | 0.0 (0.0; 0.0) | 0 [0.0]    | 0 [0.0]    | 0 [0.0]         | 0 [0.0]   | 0.0 (0.0; 0.0) |
|                           | IV    | 0 [0.0]  | 0 [0.0]  | 0 [0.0]         | 0 [0.0]  | 0.0 (0.0; 0.0) | 0 [0.0]    | 0 [0.0]    | 0 [0.0]         | 0 [0.0]   | 0.0 (0.0; 0.0) |
|                           | X/NA  | 2 [0.1]  | 0 [0.0]  | 0 [0.0]         | 2 [0.0]  | 0.0 (0.0; 0.1) | 12 [0.4]   | 0 [0.0]    | 0 [0.0]         | 12 [0.2]  | 0.2 (0.1; 0.3) |
| Papillary carcinoma 55+y  | I     | 0 [0.0]  | 84 [6.2] | 11 [2.6]        | 95 [1.7] | 1.7 (1.3; 2.0) | 0 [0.0]    | 147 [10.5] | 21 [3.3]        | 168 [2.9] | 2.8 (2.3; 3.2) |
|                           | II    | 0 [0.0]  | 15 [1.1] | 1 [0.2]         | 16 [0.3] | 0.3 (0.1; 0.4) | 0 [0.0]    | 30 [2.1]   | 4 [0.6]         | 34 [0.6]  | 0.6 (0.4; 0.7) |
|                           | III   | 0 [0.0]  | 2 [0.1]  | 1 [0.2]         | 3 [0.1]  | 0.1 (0.0; 0.1) | 0 [0.0]    | 4 [0.3]    | 3 [0.5]         | 7 [0.1]   | 0.1 (0.0; 0.2) |
|                           | IV    | 0 [0.0]  | 2 [0.1]  | 1 [0.2]         | 3 [0.1]  | 0.1 (0.0; 0.1) | 0 [0.0]    | 2 [0.1]    | 3 [0.5]         | 5 [0.1]   | 0.1 (0.0; 0.1) |
|                           | X/NA  | 0 [0.0]  | 2 [0.1]  | 2 [0.5]         | 4 [0.1]  | 0.1 (0.0; 0.1) | 0 [0.0]    | 4 [0.3]    | 0 [0.0]         | 4 [0.1]   | 0.1 (0.0; 0.1) |
| Follicular carcinoma <55y | I     | 10 [0.3] | 0 [0.0]  | 0 [0.0]         | 10 [0.2] | 0.2 (0.1; 0.3) | 32 [1.1]   | 0 [0.0]    | 0 [0.0]         | 32 [0.5]  | 0.6 (0.4; 0.8) |
|                           | II    | 0 [0.0]  | 0 [0.0]  | 0 [0.0]         | 0 [0.0]  | 0.0 (0.0; 0.0) | 0 [0.0]    | 0 [0.0]    | 0 [0.0]         | 0 [0.0]   | 0.0 (0.0; 0.0) |
|                           | III   | 0 [0.0]  | 0 [0.0]  | 0 [0.0]         | 0 [0.0]  | 0.0 (0.0; 0.0) | 0 [0.0]    | 0 [0.0]    | 0 [0.0]         | 0 [0.0]   | 0.0 (0.0; 0.0) |
|                           | IV    | 0 [0.0]  | 0 [0.0]  | 0 [0.0]         | 0 [0.0]  | 0.0 (0.0; 0.0) | 0 [0.0]    | 0 [0.0]    | 0 [0.0]         | 0 [0.0]   | 0.0 (0.0; 0.0) |
|                           | X/NA  | 4 [0.1]  | 0 [0.0]  | 0 [0.0]         | 4 [0.1]  | 0.1 (0.0; 0.1) | 5 [0.2]    | 0 [0.0]    | 0 [0.0]         | 5 [0.1]   | 0.1 (0.0; 0.2) |
| Follicular carcinoma 55+y | I     | 0 [0.0]  | 14 [1.0] | 1 [0.2]         | 15 [0.3] | 0.3 (0.1; 0.4) | 0 [0.0]    | 16 [1.1]   | 6 [0.9]         | 22 [0.4]  | 0.4 (0.2; 0.5) |
|                           | II    | 0 [0.0]  | 10 [0.7] | 7 [1.6]         | 17 [0.3] | 0.3 (0.2; 0.5) | 0 [0.0]    | 6 [0.4]    | 5 [0.8]         | 11 [0.2]  | 0.2 (0.1; 0.3) |
|                           | III   | 0 [0.0]  | 0 [0.0]  | 0 [0.0]         | 0 [0.0]  | 0.0 (0.0; 0.0) | 0 [0.0]    | 0 [0.0]    | 1 [0.2]         | 1 [0.0]   | 0.0 (0.0; 0.0) |
|                           | IV    | 0 [0.0]  | 2 [0.1]  | 2 [0.5]         | 4 [0.1]  | 0.1 (0.0; 0.2) | 0 [0.0]    | 3 [0.2]    | 3 [0.5]         | 6 [0.1]   | 0.1 (0.0; 0.2) |

| Type                        | Stage       | Males   |         |         |          | Females         |         |         |          |                 |                |
|-----------------------------|-------------|---------|---------|---------|----------|-----------------|---------|---------|----------|-----------------|----------------|
|                             |             | N[CR]   |         |         |          | ESR2013 (95%CI) |         |         |          |                 |                |
|                             |             | 15-54   | 55-74   | 75+     | All ages | 15-54           | 55-74   | 75+     | All ages | ESR2013 (95%CI) |                |
|                             | <b>X/NA</b> | 0 [0.0] | 2 [0.1] | 0 [0.0] | 2 [0.0]  | 0.0 (0.0; 0.1)  | 0 [0.0] | 3 [0.2] | 3 [0.5]  | 6 [0.1]         | 0.1 (0.0; 0.2) |
| <b>Medullary carcinoma</b>  | <b>I</b>    | 1 [0.0] | 2 [0.1] | 2 [0.5] | 5 [0.1]  | 0.1 (0.0; 0.2)  | 2 [0.1] | 6 [0.4] | 1 [0.2]  | 9 [0.2]         | 0.1 (0.0; 0.2) |
|                             | <b>II</b>   | 2 [0.1] | 0 [0.0] | 0 [0.0] | 2 [0.0]  | 0.0 (0.0; 0.1)  | 1 [0.0] | 1 [0.1] | 0 [0.0]  | 2 [0.0]         | 0.0 (0.0; 0.1) |
|                             | <b>III</b>  | 1 [0.0] | 0 [0.0] | 0 [0.0] | 1 [0.0]  | 0.0 (0.0; 0.1)  | 0 [0.0] | 0 [0.0] | 2 [0.3]  | 2 [0.0]         | 0.0 (0.0; 0.1) |
|                             | <b>IV</b>   | 1 [0.0] | 3 [0.2] | 1 [0.2] | 5 [0.1]  | 0.1 (0.0; 0.2)  | 2 [0.1] | 3 [0.2] | 1 [0.2]  | 7 [0.1]         | 0.1 (0.0; 0.2) |
|                             | <b>X/NA</b> | 0 [0.0] | 0 [0.0] | 0 [0.0] | 0 [0.0]  | 0.0 (0.0; 0.0)  | 1 [0.0] | 1 [0.1] | 0 [0.0]  | 2 [0.0]         | 0.0 (0.0; 0.1) |
| <b>Anaplastic carcinoma</b> | <b>IV</b>   | 2 [0.1] | 5 [0.4] | 7 [1.6] | 14 [0.2] | 0.3 (0.1; 0.4)  | 0 [0.0] | 4 [0.3] | 8 [1.3]  | 12 [0.2]        | 0.2 (0.1; 0.3) |
| <b>Other</b>                | <b>I</b>    | 3 [0.1] | 2 [0.1] | 1 [0.2] | 6 [0.1]  | 0.1 (0.0; 0.2)  | 5 [0.2] | 3 [0.2] | 1 [0.2]  | 9 [0.2]         | 0.2 (0.1; 0.2) |
|                             | <b>II</b>   | 0 [0.0] | 3 [0.2] | 1 [0.2] | 4 [0.1]  | 0.1 (0.0; 0.2)  | 1 [0.0] | 2 [0.1] | 3 [0.5]  | 6 [0.1]         | 0.1 (0.0; 0.2) |
|                             | <b>III</b>  | 0 [0.0] | 1 [0.1] | 1 [0.2] | 2 [0.0]  | 0.0 (0.0; 0.1)  | 0 [0.0] | 0 [0.0] | 0 [0.0]  | 0 [0.0]         | 0.0 (0.0; 0.0) |
|                             | <b>IV</b>   | 0 [0.0] | 2 [0.1] | 2 [0.5] | 4 [0.1]  | 0.1 (0.0; 0.1)  | 0 [0.0] | 5 [0.4] | 2 [0.3]  | 7 [0.1]         | 0.1 (0.0; 0.2) |
|                             | <b>X/NA</b> | 0 [0.0] | 2 [0.1] | 2 [0.5] | 4 [0.1]  | 0.1 (0.0; 0.1)  | 0 [0.0] | 2 [0.1] | 3 [0.5]  | 5 [0.1]         | 0.1 (0.0; 0.1) |

## 2. CANCER INCIDENCE TRENDS



### 2.1. Thyroid cancer incidence trends: by region

2.1.1. *Thyroid cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022*

| Region   | 2004           | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | AAPC, % (95%CI) | Period          |                    |           |
|----------|----------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-----------------|-----------------|--------------------|-----------|
| Belgium  | <b>N</b>       | 157  | 169  | 177  | 189  | 214  | 258  | 205  | 241  | 250  | 252  | 268  | 282  | 267  | 291  | 254  | 262  | 230  | 309  | 303             |                 |                    |           |
|          | <b>CR</b>      | 3.1  | 3.3  | 3.4  | 3.6  | 4.1  | 4.9  | 3.9  | 4.5  | 4.6  | 4.6  | 4.9  | 5.1  | 4.8  | 5.2  | 4.5  | 4.7  | 4.1  | 5.4  | 5.3             |                 |                    |           |
|          | <b>ESR2013</b> | 3.3  | 3.6  | 3.7  | 3.8  | 4.4  | 5.2  | 4.0  | 4.8  | 4.8  | 4.9  | 5.2  | 5.3  | 5.1  | 5.4  | 4.7  | 4.9  | 4.3  | 5.6  | 5.4             | 2.1 (1.3; 2.9)  | 2004-2022          |           |
|          |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 | 4.5 (2.8; 6.3)  | 2004-2013          |           |
|          |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 |                 | -0.2 (-1.9; 1.5)   | 2014-2022 |
| Brussels | <b>N</b>       | 23   | 17   | 21   | 25   | 33   | 28   | 29   | 27   | 35   | 37   | 42   | 35   | 31   | 36   | 35   | 32   | 19   | 36   | 22              |                 |                    |           |
|          | <b>CR</b>      | 4.8  | 3.5  | 4.3  | 5.0  | 6.5  | 5.4  | 5.5  | 5.0  | 6.3  | 6.6  | 7.4  | 6.1  | 5.3  | 6.2  | 6.0  | 5.4  | 3.2  | 6.0  | 3.7             |                 |                    |           |
|          | <b>ESR2013</b> | 5.9  | 3.8  | 5.2  | 5.8  | 7.5  | 6.7  | 6.5  | 6.5  | 7.9  | 8.2  | 8.6  | 8.1  | 6.8  | 8.0  | 7.4  | 6.2  | 4.1  | 8.0  | 4.5             | 0.4 (-1.2; 2.0) | 2004-2022          |           |
|          |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 | 6.0 (2.7; 9.4)  | 2004-2014          |           |
|          |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 |                 | -6.2 (-10.0; -2.4) | 2015-2022 |
| Flanders | <b>N</b>       | 64   | 69   | 79   | 77   | 91   | 109  | 92   | 133  | 116  | 111  | 119  | 125  | 128  | 151  | 129  | 134  | 131  | 168  | 158             |                 |                    |           |
|          | <b>CR</b>      | 2.2  | 2.3  | 2.6  | 2.6  | 3.0  | 3.6  | 3.0  | 4.3  | 3.7  | 3.5  | 3.8  | 3.9  | 4.0  | 4.7  | 4.0  | 4.1  | 4.0  | 5.1  | 4.8             |                 |                    |           |
|          | <b>ESR2013</b> | 2.4  | 2.5  | 2.7  | 2.6  | 3.1  | 3.7  | 3.0  | 4.5  | 3.8  | 3.7  | 4.0  | 3.9  | 4.1  | 4.7  | 4.0  | 4.2  | 4.0  | 5.2  | 4.7             | 3.9 (3.0; 4.7)  | 2004-2022          |           |
|          |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 | 7.2 (4.7; 9.8)  | 2004-2011          |           |
|          |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 |                 | 1.8 (0.4; 3.2)     | 2012-2022 |

| Region            | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | AAPC, % (95%CI) | Period    |
|-------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-----------------|-----------|
| Wallonia <b>N</b> | 70   | 83   | 77   | 87   | 90   | 121  | 84   | 81   | 99   | 104  | 107  | 122  | 108  | 104  | 90   | 96   | 80   | 105  | 123  |                 |           |
| <b>CR</b>         | 4.3  | 5.0  | 4.6  | 5.2  | 5.4  | 7.2  | 4.9  | 4.7  | 5.7  | 6.0  | 6.1  | 7.0  | 6.1  | 5.9  | 5.1  | 5.4  | 4.5  | 5.9  | 6.9  |                 |           |
| <b>ESR2013</b>    | 4.5  | 5.6  | 5.0  | 5.6  | 5.9  | 7.6  | 5.3  | 4.9  | 6.1  | 6.4  | 6.6  | 7.3  | 6.5  | 6.3  | 5.3  | 5.8  | 4.6  | 6.0  | 7.0  | 0.8 (-0.5; 2.1) | 2004-2022 |

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Thyroid cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

| Region            | 2004           | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | AAPC, % (95%CI) | Period          |                   |           |
|-------------------|----------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-----------------|-----------------|-------------------|-----------|
| Belgium <b>N</b>  | 474            | 500  | 511  | 513  | 547  | 635  | 653  | 671  | 707  | 694  | 807  | 746  | 776  | 754  | 722  | 707  | 589  | 763  | 735  |                 |                 |                   |           |
|                   | <b>CR</b>      | 8.9  | 9.4  | 9.5  | 9.5  | 10.1 | 11.6 | 11.8 | 12.0 | 12.6 | 12.3 | 14.2 | 13.1 | 13.5 | 13.1 | 12.5 | 12.2 | 10.1 | 13.1 | 12.5            |                 |                   |           |
|                   | <b>ESR2013</b> | 9.1  | 9.5  | 9.7  | 9.6  | 10.3 | 11.8 | 12.0 | 12.3 | 12.8 | 12.5 | 14.5 | 13.3 | 13.8 | 13.4 | 12.7 | 12.4 | 10.3 | 13.2 | 12.7            | 1.6 (1.0; 2.2)  | 2004-2022         |           |
|                   |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 | 4.5 (3.3; 5.6)  | 2004-2014         |           |
|                   |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 |                 | -1.9 (-3.2; -0.5) | 2015-2022 |
| Brussels <b>N</b> | 77             | 54   | 63   | 87   | 65   | 98   | 88   | 104  | 133  | 109  | 135  | 108  | 112  | 109  | 104  | 86   | 77   | 83   | 94   |                 |                 |                   |           |
|                   | <b>CR</b>      | 14.8 | 10.3 | 11.9 | 16.3 | 12.0 | 17.7 | 15.6 | 18.0 | 22.7 | 18.4 | 22.6 | 17.9 | 18.4 | 17.9 | 17.0 | 14.0 | 12.4 | 13.4 | 15.1            |                 |                   |           |
|                   | <b>ESR2013</b> | 16.5 | 11.4 | 12.5 | 17.7 | 13.2 | 19.7 | 17.1 | 20.1 | 24.2 | 20.6 | 26.0 | 19.6 | 20.1 | 19.3 | 18.7 | 15.5 | 13.2 | 14.6 | 16.7            | 0.4 (-0.9; 1.7) | 2004-2022         |           |
|                   |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 | 6.0 (3.4; 8.7)  | 2004-2014         |           |
|                   |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 |                 | -6.2 (-9.2; -3.1) | 2015-2022 |
| Flanders <b>N</b> | 166            | 227  | 218  | 206  | 222  | 261  | 285  | 325  | 319  | 303  | 380  | 369  | 379  | 343  | 347  | 368  | 307  | 398  | 370  |                 |                 |                   |           |
|                   | <b>CR</b>      | 5.4  | 7.4  | 7.1  | 6.6  | 7.1  | 8.3  | 9.0  | 10.2 | 9.9  | 9.4  | 11.7 | 11.3 | 11.6 | 10.4 | 10.5 | 11.1 | 9.2  | 11.8 | 10.9            |                 |                   |           |
|                   | <b>ESR2013</b> | 5.5  | 7.3  | 7.1  | 6.6  | 7.1  | 8.3  | 8.9  | 10.2 | 9.9  | 9.3  | 11.6 | 11.4 | 11.7 | 10.4 | 10.4 | 11.1 | 9.2  | 11.8 | 11.0            | 3.1 (2.3; 3.9)  | 2004-2022         |           |
|                   |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 | 5.9 (4.5; 7.4)  | 2004-2015         |           |
|                   |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 |                 | -1.3 (-3.5; 1.0)  | 2016-2022 |
| Wallonia <b>N</b> | 231            | 219  | 230  | 220  | 260  | 276  | 280  | 242  | 255  | 282  | 292  | 269  | 285  | 302  | 271  | 253  | 205  | 282  | 271  |                 |                 |                   |           |
|                   | <b>CR</b>      | 13.3 | 12.5 | 13.1 | 12.4 | 14.6 | 15.4 | 15.6 | 13.4 | 14.0 | 15.4 | 15.9 | 14.6 | 15.4 | 16.3 | 14.6 | 13.6 | 11.0 | 15.1 | 14.5            |                 |                   |           |
|                   | <b>ESR2013</b> | 13.6 | 13.0 | 13.5 | 12.9 | 15.2 | 16.1 | 16.0 | 13.9 | 14.4 | 15.8 | 16.5 | 15.0 | 15.9 | 16.9 | 14.9 | 13.9 | 11.3 | 15.4 | 14.8            | 0.2 (-0.6; 1.0) | 2004-2022         |           |
|                   |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 | 1.9 (0.3; 3.6)  | 2004-2014         |           |
|                   |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 |                 | -1.9 (-3.9; 0.1)  | 2015-2022 |

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.2. Thyroid cancer incidence trends: by tumour stage

2.2.1. Thyroid cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

| Stage      | Males          |      |      |      |      |                 |                      | Females            |           |      |      |      |                    |                      |                     |           |
|------------|----------------|------|------|------|------|-----------------|----------------------|--------------------|-----------|------|------|------|--------------------|----------------------|---------------------|-----------|
|            | 2018           | 2019 | 2020 | 2021 | 2022 | AAPC, % (95%CI) | Period               | 2018               | 2019      | 2020 | 2021 | 2022 | AAPC, % (95%CI)    | Period               |                     |           |
| <b>I</b>   | <b>N</b>       | 177  | 184  | 148  | 211  | 211             |                      | 609                | 565       | 491  | 659  | 600  |                    |                      |                     |           |
|            | <b>CR</b>      | 3.2  | 3.3  | 2.6  | 3.7  | 3.7             |                      | 10.5               | 9.7       | 8.4  | 11.3 | 10.2 |                    |                      |                     |           |
|            | <b>ESR2013</b> |      | 3.2  | 3.4  | 2.7  | 3.8             | 3.7                  | 8.4 (6.9; 9.9)     | 2004-2022 | 10.8 | 10.0 | 8.7  | 11.5               | 10.5                 | 7.0 (6.0; 8.0)      | 2004-2022 |
|            |                |      |      |      |      |                 |                      | 13.3 (9.8; 16.9)   | 2004-2013 |      |      |      |                    |                      | 14.8 (11.7; 17.9)   | 2004-2011 |
|            |                |      |      |      |      |                 | 3.7 (0.5; 7.0)       | 2014-2022          |           |      |      |      |                    | 4.3 (0.1; 8.7)       | 2012-2015           |           |
|            |                |      |      |      |      |                 |                      |                    |           |      |      |      | 1.2 (-1.5; 4.0)    | 2016-2022            |                     |           |
| <b>II</b>  | <b>N</b>       | 38   | 36   | 44   | 55   | 40              |                      | 52                 | 58        | 45   | 50   | 54   |                    |                      |                     |           |
|            | <b>CR</b>      | 0.7  | 0.6  | 0.8  | 1.0  | 0.7             |                      | 0.9                | 1.0       | 0.8  | 0.9  | 0.9  |                    |                      |                     |           |
|            | <b>ESR2013</b> |      | 0.7  | 0.6  | 0.8  | 1.0             | 0.7                  | 8.2 (5.6; 10.8)    | 2004-2022 | 0.9  | 1.0  | 0.7  | 0.8                | 0.9                  | 2.0 (0.8; 3.3)      | 2004-2022 |
|            |                |      |      |      |      |                 |                      |                    |           |      |      |      |                    |                      | 7.9 (5.7; 10.2)     | 2004-2015 |
|            |                |      |      |      |      |                 |                      |                    |           |      |      |      |                    | -6.6 (-9.8; -3.2)    | 2016-2022           |           |
| <b>III</b> | <b>N</b>       | 4    | 10   | 5    | 7    | 6               |                      | 8                  | 5         | 8    | 5    | 10   |                    |                      |                     |           |
|            | <b>CR</b>      | 0.1  | 0.2  | 0.1  | 0.1  | 0.1             |                      | 0.1                | 0.1       | 0.1  | 0.1  | 0.2  |                    |                      |                     |           |
|            | <b>ESR2013</b> |      | 0.1  | 0.2  | 0.1  | 0.1             | 0.1                  | -9.3 (-12.8; -5.6) | 2004-2022 | 0.1  | 0.1  | 0.1  | 0.1                | 0.1                  | -10.1 (-15.2; -4.6) | 2004-2022 |
|            |                |      |      |      |      |                 |                      | 7.4 (-1.8; 17.4)   | 2004-2013 |      |      |      |                    |                      | 11.0 (-1.2; 24.8)   | 2004-2013 |
|            |                |      |      |      |      |                 | -23.3 (-29.9; -16.2) | 2014-2022          |           |      |      |      |                    | -37.9 (-51.8; -20.1) | 2014-2017           |           |
|            |                |      |      |      |      |                 |                      |                    |           |      |      |      | -17.2 (-35.3; 5.8) | 2018-2022            |                     |           |
| <b>IV</b>  | <b>N</b>       | 22   | 21   | 25   | 26   | 30              |                      | 29                 | 45        | 29   | 36   | 37   |                    |                      |                     |           |
|            | <b>CR</b>      | 0.4  | 0.4  | 0.4  | 0.5  | 0.5             |                      | 0.5                | 0.8       | 0.5  | 0.6  | 0.6  |                    |                      |                     |           |
|            | <b>ESR2013</b> | 0.4  | 0.4  | 0.5  | 0.5  | 0.6             | -1.8 (-3.6; 0.0)     | 2004-2022          | 0.5       | 0.7  | 0.4  | 0.6  | 0.6                | -1.5 (-3.2; 0.2)     | 2004-2022           |           |

| Stage       | Males          |      |      |      |      |                   |                     | Females   |      |      |      |      |                     |                      |           |
|-------------|----------------|------|------|------|------|-------------------|---------------------|-----------|------|------|------|------|---------------------|----------------------|-----------|
|             | 2018           | 2019 | 2020 | 2021 | 2022 | AAPC, % (95%CI)   | Period              | 2018      | 2019 | 2020 | 2021 | 2022 | AAPC, % (95%CI)     | Period               |           |
|             |                |      |      |      |      | 3.5 (-1.2; 8.5)   | 2004-2012           |           |      |      |      |      | 1.3 (-1.6; 4.3)     | 2004-2014            |           |
|             |                |      |      |      |      | -5.8 (-9.2; -2.4) | 2013-2022           |           |      |      |      |      | -12.2 (-18.4; -5.5) | 2015-2018            |           |
|             |                |      |      |      |      |                   |                     |           |      |      |      |      | 2.9 (-6.1; 12.9)    | 2019-2022            |           |
| <b>X/NA</b> | <b>N</b>       | 13   | 11   | 8    | 10   | 16                |                     | 24        | 34   | 16   | 13   | 34   |                     |                      |           |
|             | <b>CR</b>      | 0.2  | 0.2  | 0.1  | 0.2  | 0.3               |                     | 0.4       | 0.6  | 0.3  | 0.2  | 0.6  |                     |                      |           |
|             | <b>ESR2013</b> | 0.2  | 0.2  | 0.2  | 0.2  | 0.3               | -11.1 (-12.7; -9.4) | 2004-2022 | 0.4  | 0.6  | 0.3  | 0.2  | 0.6                 | -14.0 (-16.0; -11.9) | 2004-2022 |

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



## 2.3. Thyroid cancer incidence trends: by tumour type

2.3.1. Thyroid cancer incidence trends in males by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

| Type                 |                | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | AAPC, % (95%CI)  | Period           |           |
|----------------------|----------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------------------|------------------|-----------|
| Papillary carcinoma  | <b>N</b>       | 101  | 113  | 119  | 126  | 129  | 181  | 139  | 168  | 187  | 187  | 199  | 222  | 194  | 221  | 191  | 194  | 157  | 230  | 204  |                  |                  |           |
|                      | <b>CR</b>      | 2.0  | 2.2  | 2.3  | 2.4  | 2.5  | 3.4  | 2.6  | 3.1  | 3.5  | 3.4  | 3.6  | 4.0  | 3.5  | 4.0  | 3.4  | 3.4  | 2.8  | 4.1  | 3.6  |                  |                  |           |
|                      | <b>ESR2013</b> | 2.1  | 2.4  | 2.4  | 2.5  | 2.5  | 3.6  | 2.7  | 3.3  | 3.6  | 3.6  | 3.8  | 4.1  | 3.6  | 4.1  | 3.5  | 3.6  | 2.9  | 4.1  | 3.6  | 2.7 (1.8; 3.7)   | 2004-2022        |           |
|                      |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      | 6.2 (4.3; 8.1)   | 2004-2014        |           |
|                      |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                  | -1.4 (-3.6; 0.9) | 2015-2022 |
| Follicular carcinoma | <b>N</b>       | 28   | 27   | 34   | 35   | 36   | 37   | 28   | 34   | 30   | 31   | 43   | 36   | 38   | 40   | 31   | 41   | 36   | 44   | 52   |                  |                  |           |
|                      | <b>CR</b>      | 0.6  | 0.5  | 0.7  | 0.7  | 0.7  | 0.7  | 0.5  | 0.6  | 0.6  | 0.6  | 0.8  | 0.7  | 0.7  | 0.7  | 0.6  | 0.7  | 0.6  | 0.8  | 0.9  |                  |                  |           |
|                      | <b>ESR2013</b> | 0.6  | 0.5  | 0.7  | 0.7  | 0.7  | 0.8  | 0.6  | 0.7  | 0.6  | 0.6  | 0.9  | 0.7  | 0.7  | 0.7  | 0.6  | 0.8  | 0.7  | 0.8  | 0.9  | 1.1 (-0.2; 2.4)  | 2004-2022        |           |
| Medullary carcinoma  | <b>N</b>       | 9    | 16   | 17   | 15   | 22   | 18   | 18   | 20   | 19   | 11   | 11   | 15   | 13   | 14   | 15   | 16   | 16   | 15   | 13   |                  |                  |           |
|                      | <b>CR</b>      | 0.2  | 0.3  | 0.3  | 0.3  | 0.4  | 0.3  | 0.3  | 0.4  | 0.4  | 0.2  | 0.2  | 0.3  | 0.2  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.2  |                  |                  |           |
|                      | <b>ESR2013</b> | 0.2  | 0.4  | 0.4  | 0.3  | 0.5  | 0.4  | 0.4  | 0.4  | 0.4  | 0.2  | 0.2  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.2  | -1.5 (-3.4; 0.4) | 2004-2022        |           |
| Anaplastic carcinoma | <b>N</b>       | 6    | 8    | 2    | 9    | 18   | 16   | 9    | 6    | 7    | 9    | 6    | 3    | 8    | 7    | 9    | 3    | 11   | 10   | 14   |                  |                  |           |
|                      | <b>CR</b>      | 0.1  | 0.2  | 0.0  | 0.2  | 0.3  | 0.3  | 0.2  | 0.1  | 0.1  | 0.2  | 0.1  | 0.1  | 0.1  | 0.1  | 0.2  | 0.1  | 0.2  | 0.2  | 0.2  |                  |                  |           |
|                      | <b>ESR2013</b> | 0.1  | 0.2  | 0.0  | 0.2  | 0.4  | 0.4  | 0.2  | 0.1  | 0.1  | 0.2  | 0.1  | 0.1  | 0.2  | 0.1  | 0.2  | 0.1  | 0.2  | 0.2  | 0.3  | 0.0 (-4.9; 5.2)  | 2004-2022        |           |
| Other                | <b>N</b>       | 13   | 5    | 5    | 4    | 9    | 6    | 11   | 13   | 7    | 14   | 9    | 6    | 14   | 9    | 8    | 8    | 10   | 10   | 20   |                  |                  |           |
|                      | <b>CR</b>      | 0.3  | 0.1  | 0.1  | 0.1  | 0.2  | 0.1  | 0.2  | 0.2  | 0.1  | 0.3  | 0.2  | 0.1  | 0.3  | 0.2  | 0.1  | 0.1  | 0.2  | 0.2  | 0.4  |                  |                  |           |
|                      | <b>ESR2013</b> | 0.3  | 0.1  | 0.1  | 0.1  | 0.2  | 0.1  | 0.2  | 0.3  | 0.1  | 0.3  | 0.2  | 0.1  | 0.3  | 0.2  | 0.1  | 0.2  | 0.2  | 0.2  | 0.4  | 2.2 (-1.1; 5.7)  | 2004-2022        |           |

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.2. Thyroid cancer incidence trends in females by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

| Type                 |                | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | AAPC, % (95%CI)  | Period            |           |
|----------------------|----------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------------------|-------------------|-----------|
| Papillary carcinoma  | <b>N</b>       | 347  | 380  | 426  | 391  | 439  | 499  | 515  | 558  | 590  | 566  | 685  | 630  | 652  | 609  | 608  | 574  | 477  | 642  | 591  |                  |                   |           |
|                      | <b>CR</b>      | 6.5  | 7.1  | 7.9  | 7.2  | 8.1  | 9.1  | 9.3  | 10.0 | 10.5 | 10.0 | 12.1 | 11.0 | 11.4 | 10.6 | 10.5 | 9.9  | 8.2  | 11.0 | 10.1 |                  |                   |           |
|                      | <b>ESR2013</b> | 6.6  | 7.2  | 8.1  | 7.4  | 8.2  | 9.3  | 9.5  | 10.2 | 10.7 | 10.2 | 12.3 | 11.3 | 11.6 | 10.9 | 10.8 | 10.1 | 8.4  | 11.1 | 10.3 | 2.0 (1.4; 2.7)   | 2004-2022         |           |
|                      |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      | 5.6 (4.3; 6.9)   | 2004-2014         |           |
|                      |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                  | -2.2 (-3.8; -0.7) | 2015-2022 |
| Follicular carcinoma | <b>N</b>       | 76   | 61   | 48   | 70   | 68   | 78   | 81   | 62   | 67   | 81   | 80   | 81   | 73   | 91   | 64   | 76   | 64   | 63   | 83   |                  |                   |           |
|                      | <b>CR</b>      | 1.4  | 1.1  | 0.9  | 1.3  | 1.2  | 1.4  | 1.5  | 1.1  | 1.2  | 1.4  | 1.4  | 1.4  | 1.3  | 1.6  | 1.1  | 1.3  | 1.1  | 1.1  | 1.4  |                  |                   |           |
|                      | <b>ESR2013</b> | 1.5  | 1.2  | 0.9  | 1.3  | 1.3  | 1.4  | 1.5  | 1.1  | 1.2  | 1.5  | 1.4  | 1.5  | 1.3  | 1.6  | 1.1  | 1.3  | 1.1  | 1.1  | 1.4  |                  |                   |           |
|                      |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      | 0.0 (-1.3; 1.3)  | 2004-2022         |           |
| Medullary carcinoma  | <b>N</b>       | 25   | 23   | 17   | 20   | 22   | 23   | 25   | 28   | 20   | 18   | 23   | 10   | 23   | 19   | 20   | 22   | 22   | 27   | 22   |                  |                   |           |
|                      | <b>CR</b>      | 0.5  | 0.4  | 0.3  | 0.4  | 0.4  | 0.4  | 0.5  | 0.5  | 0.4  | 0.3  | 0.4  | 0.2  | 0.4  | 0.3  | 0.3  | 0.4  | 0.4  | 0.5  | 0.4  |                  |                   |           |
|                      | <b>ESR2013</b> | 0.5  | 0.4  | 0.3  | 0.4  | 0.4  | 0.4  | 0.5  | 0.5  | 0.4  | 0.3  | 0.4  | 0.2  | 0.4  | 0.3  | 0.3  | 0.4  | 0.4  | 0.5  | 0.4  |                  |                   |           |
|                      |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      | -1.0 (-3.1; 1.1) | 2004-2022         |           |
| Anaplastic carcinoma | <b>N</b>       | 12   | 19   | 9    | 16   | 12   | 17   | 11   | 14   | 10   | 12   | 4    | 10   | 10   | 8    | 12   | 12   | 10   | 14   | 12   |                  |                   |           |
|                      | <b>CR</b>      | 0.2  | 0.4  | 0.2  | 0.3  | 0.2  | 0.3  | 0.2  | 0.3  | 0.2  | 0.2  | 0.1  | 0.2  | 0.2  | 0.1  | 0.2  | 0.2  | 0.2  | 0.2  | 0.2  |                  |                   |           |
|                      | <b>ESR2013</b> | 0.2  | 0.3  | 0.2  | 0.3  | 0.2  | 0.3  | 0.2  | 0.2  | 0.2  | 0.2  | 0.1  | 0.1  | 0.2  | 0.1  | 0.2  | 0.2  | 0.1  | 0.2  | 0.2  |                  |                   |           |
|                      |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      | -1.3 (-5.0; 2.5) | 2004-2022         |           |
|                      |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                  | -4.6 (-8.3; -0.8) | 2004-2019 |
|                      |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                  | 16.6 (-9.0; 49.4) | 2020-2022 |
| Other                | <b>N</b>       | 14   | 17   | 11   | 16   | 6    | 18   | 21   | 9    | 20   | 17   | 15   | 15   | 18   | 27   | 18   | 23   | 16   | 17   | 27   |                  |                   |           |
|                      | <b>CR</b>      | 0.3  | 0.3  | 0.2  | 0.3  | 0.1  | 0.3  | 0.4  | 0.2  | 0.4  | 0.3  | 0.3  | 0.3  | 0.3  | 0.5  | 0.3  | 0.4  | 0.3  | 0.3  | 0.5  |                  |                   |           |
|                      | <b>ESR2013</b> | 0.3  | 0.3  | 0.2  | 0.3  | 0.1  | 0.3  | 0.4  | 0.2  | 0.4  | 0.3  | 0.2  | 0.3  | 0.3  | 0.5  | 0.3  | 0.4  | 0.3  | 0.3  | 0.4  |                  |                   |           |
|                      |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      | 2.2 (-0.5; 5.1)  | 2004-2022         |           |

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.4. Thyroid cancer incidence trends: by age group

2.4.1. Thyroid cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

| Age          | 2004           | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | AAPC, % (95%CI) | Period         |                  |           |
|--------------|----------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-----------------|----------------|------------------|-----------|
| <b>15-54</b> | <b>N</b>       | 76   | 89   | 89   | 104  | 100  | 119  | 100  | 108  | 132  | 103  | 128  | 139  | 109  | 129  | 101  | 114  | 96   | 122  | 106             |                |                  |           |
|              | <b>CR</b>      | 2.6  | 3.1  | 3.1  | 3.6  | 3.4  | 4.1  | 3.4  | 3.7  | 4.5  | 3.5  | 4.3  | 4.7  | 3.7  | 4.4  | 3.4  | 3.9  | 3.3  | 4.2  | 3.6             |                |                  |           |
|              | <b>ESR2013</b> | 2.6  | 3.1  | 3.1  | 3.6  | 3.4  | 4.1  | 3.4  | 3.7  | 4.5  | 3.5  | 4.3  | 4.7  | 3.7  | 4.4  | 3.4  | 3.9  | 3.3  | 4.2  | 3.7             | 1.1 (0.2; 2.1) | 2004-2022        |           |
|              |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 | 3.8 (1.9; 5.7) | 2004-2014        |           |
|              |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 |                | -2.0 (-4.3; 0.3) | 2015-2022 |
| <b>55-74</b> | <b>N</b>       | 67   | 66   | 74   | 68   | 82   | 108  | 82   | 99   | 94   | 120  | 117  | 116  | 127  | 128  | 124  | 115  | 98   | 144  | 153             |                |                  |           |
|              | <b>CR</b>      | 6.7  | 6.5  | 7.2  | 6.6  | 7.8  | 10.1 | 7.6  | 9.0  | 8.4  | 10.5 | 10.1 | 9.8  | 10.5 | 10.3 | 9.8  | 8.9  | 7.4  | 10.8 | 11.3            |                |                  |           |
|              | <b>ESR2013</b> | 6.7  | 6.5  | 7.2  | 6.4  | 7.9  | 10.2 | 7.6  | 9.1  | 8.5  | 10.7 | 10.3 | 9.7  | 10.6 | 10.4 | 9.8  | 9.1  | 7.6  | 10.8 | 11.4            | 2.5 (1.4; 3.5) | 2004-2022        |           |
|              |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 | 5.1 (2.6; 7.6) | 2004-2013        |           |
|              |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 |                | -0.1 (-2.4; 2.3) | 2014-2022 |
| <b>75+</b>   | <b>N</b>       | 14   | 14   | 13   | 15   | 30   | 31   | 21   | 34   | 24   | 28   | 22   | 27   | 31   | 33   | 27   | 30   | 36   | 41   | 43              |                |                  |           |
|              | <b>CR</b>      | 4.8  | 4.6  | 4.1  | 4.6  | 8.9  | 9.0  | 5.9  | 9.4  | 6.5  | 7.4  | 5.7  | 6.9  | 7.9  | 8.4  | 6.8  | 7.4  | 8.7  | 9.9  | 10.0            |                |                  |           |
|              | <b>ESR2013</b> | 4.8  | 4.9  | 4.0  | 4.7  | 8.2  | 8.1  | 5.3  | 8.6  | 6.0  | 7.2  | 6.4  | 6.5  | 7.7  | 7.9  | 6.7  | 7.7  | 8.9  | 9.9  | 9.9             | 3.6 (2.0; 5.3) | 2004-2022        |           |

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4.2. Thyroid cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

| Age          | 2004           | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | AAPC, % (95%CI) | Period         |                   |           |
|--------------|----------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-----------------|----------------|-------------------|-----------|
| <b>15-54</b> | <b>N</b>       | 284  | 297  | 321  | 319  | 317  | 369  | 364  | 411  | 426  | 386  | 477  | 425  | 454  | 427  | 393  | 382  | 349  | 421  | 420             |                |                   |           |
|              | <b>CR</b>      | 10.1 | 10.5 | 11.3 | 11.2 | 11.1 | 12.8 | 12.6 | 14.1 | 14.6 | 13.2 | 16.4 | 14.6 | 15.6 | 14.7 | 13.6 | 13.2 | 12.1 | 14.6 | 14.5            |                |                   |           |
|              | <b>ESR2013</b> | 10.1 | 10.5 | 11.4 | 11.2 | 11.1 | 12.9 | 12.7 | 14.2 | 14.7 | 13.3 | 16.5 | 14.7 | 15.8 | 14.9 | 13.6 | 13.3 | 12.2 | 14.7 | 14.7            | 1.5 (0.9; 2.1) | 2004-2022         |           |
|              |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 | 3.8 (2.7; 4.9) | 2004-2015         |           |
|              |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 |                | -2.0 (-3.8; -0.2) | 2016-2022 |
| <b>55-74</b> | <b>N</b>       | 146  | 150  | 147  | 156  | 186  | 209  | 217  | 200  | 211  | 238  | 262  | 265  | 251  | 256  | 264  | 259  | 184  | 267  | 242             |                |                   |           |
|              | <b>CR</b>      | 13.3 | 13.6 | 13.2 | 14.0 | 16.5 | 18.3 | 18.8 | 17.0 | 17.7 | 19.6 | 21.3 | 21.2 | 19.7 | 19.6 | 19.8 | 19.1 | 13.4 | 19.1 | 17.2            |                |                   |           |
|              | <b>ESR2013</b> | 13.3 | 13.6 | 13.2 | 14.0 | 16.4 | 18.3 | 18.7 | 17.1 | 17.7 | 19.4 | 21.1 | 21.0 | 19.7 | 19.6 | 19.9 | 19.1 | 13.4 | 19.1 | 17.3            | 1.4 (0.6; 2.3) | 2004-2022         |           |
|              |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 | 5.0 (3.3; 6.7) | 2004-2014         |           |
|              |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |                 |                | -2.8 (-4.9; -0.8) | 2015-2022 |
| <b>75+</b>   | <b>N</b>       | 42   | 52   | 39   | 35   | 43   | 54   | 68   | 57   | 67   | 63   | 64   | 54   | 69   | 70   | 60   | 64   | 53   | 72   | 70              |                |                   |           |
|              | <b>CR</b>      | 8.1  | 9.8  | 7.2  | 6.3  | 7.5  | 9.3  | 11.6 | 9.6  | 11.2 | 10.4 | 10.5 | 8.8  | 11.2 | 11.4 | 9.8  | 10.4 | 8.5  | 11.6 | 11.0            |                |                   |           |
|              | <b>ESR2013</b> | 8.1  | 9.6  | 7.4  | 6.3  | 7.7  | 9.2  | 11.3 | 9.7  | 11.6 | 10.9 | 10.7 | 9.0  | 11.5 | 12.6 | 10.4 | 11.3 | 8.8  | 12.2 | 11.6            | 2.2 (0.9; 3.6) | 2004-2022         |           |

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



#### 3.1. Thyroid cancer prevalence: by region

3.1.1. Thyroid cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022

| Region   |                | Males  |        |         |         | Females |        |         |         |
|----------|----------------|--------|--------|---------|---------|---------|--------|---------|---------|
|          |                | 1-year | 5-year | 10-year | 15-year | 1-year  | 5-year | 10-year | 15-year |
| Belgium  | <b>N</b>       | 284    | 1,214  | 2,265   | 3,033   | 712     | 3,298  | 6,600   | 9,191   |
|          | <b>CR</b>      | 4.9    | 21.1   | 39.3    | 53      | 12.0    | 55.6   | 111.2   | 155     |
|          | <b>ESR2013</b> | 5.0    | 21.5   | 40.3    | 54.1    | 12.2    | 56.3   | 112.1   | 155.3   |
| Brussels | <b>N</b>       | 22     | 127    | 264     | 364     | 93      | 419    | 906     | 1,290   |
|          | <b>CR</b>      | 3.6    | 20.9   | 43.4    | 59.8    | 14.7    | 66.2   | 143.1   | 203.8   |
|          | <b>ESR2013</b> | 4.5    | 26.1   | 55.5    | 77.8    | 16.4    | 73.7   | 163.2   | 235.2   |
| Flanders | <b>N</b>       | 146    | 642    | 1,119   | 1,457   | 353     | 1,666  | 3,200   | 4,303   |
|          | <b>CR</b>      | 4.4    | 19.2   | 33.4    | 43.5    | 10.3    | 48.7   | 93.5    | 125.7   |
|          | <b>ESR2013</b> | 4.3    | 19.0   | 33.2    | 43.3    | 10.5    | 48.8   | 93.1    | 124.3   |
| Wallonia | <b>N</b>       | 116    | 445    | 882     | 1,212   | 266     | 1,213  | 2,494   | 3,598   |
|          | <b>CR</b>      | 6.4    | 24.7   | 49.0    | 67.3    | 14.1    | 64.5   | 132.6   | 191.3   |
|          | <b>ESR2013</b> | 6.5    | 25.3   | 50.5    | 69.5    | 14.4    | 65.2   | 133.3   | 190.9   |



### 4.1. Thyroid cancer survival: by region

4.1.1. *Thyroid cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022*

| Net Survival Probability, 2013-2022 |          |           |                         |                        |                       |                       |
|-------------------------------------|----------|-----------|-------------------------|------------------------|-----------------------|-----------------------|
| Region                              | Age      | N at risk | 1-y (95%CI)             | 3-y (95%CI)            | 5-y (95%CI)           | 10-y (95%CI)          |
| Total                               | All      | 9,906     | 96.4% (96.0%; 96.8%)    | 95.5% (94.9%; 96.1%)   | 94.8% (94.1%; 95.6%)  | 93.9% (92.2%; 95.7%)  |
| Males                               |          |           |                         |                        |                       |                       |
| Belgium                             | All ages | 2,682     | 94.9% (93.9%; 95.9%)    | 92.5% (91.1%; 93.9%)   | 91.3% (89.6%; 93.1%)  | 86.2% (81.3%; 91.4%)  |
|                                     | 15-54    | 1,136     | 99.3% (98.8%; 99.9%)    | 98.8% (98.1%; 99.6%)   | 98.0% (96.9%; 99.2%)  | 95.7% (93.3%; 98.2%)  |
|                                     | 55-74    | 1,231     | 94.7% (93.3%; 96.2%)    | 91.8% (89.8%; 93.9%)   | 90.7% (88.2%; 93.3%)  | 86.9% (81.7%; 92.4%)  |
|                                     | 75+      | 315       | 79.6% (74.5%; 85.0%)    | 72.0% (64.9%; 79.8%)   | 69.5% (59.7%; 80.9%)  | 36.4% (16.6%; 79.5%)  |
| Brussels                            | All ages | 317       | 96.7% (94.4%; 99.0%)    | 94.7% (91.3%; 98.3%)   | 92.4% (88.0%; 97.0%)  | 94.6% (88.5%; 101.0%) |
|                                     | 15-54    | 153       | 100.2% (100.2%; 100.2%) | 100.0% (98.6%; 101.3%) | 99.6% (97.4%; 101.9%) | 97.1% (91.7%; 102.8%) |
|                                     | 55-74    | 142       | 94.3% (90.1%; 98.7%)    | 93.5% (88.2%; 99.2%)   | 90.5% (83.5%; 98.2%)  | 97.0% (87.3%; 107.8%) |
|                                     | 75+      | 22        | N<50                    | N<50                   | N<50                  | N<50                  |
| Flanders                            | All ages | 1,331     | 93.6% (92.1%; 95.1%)    | 91.3% (89.2%; 93.4%)   | 90.2% (87.4%; 93.0%)  | 86.0% (77.2%; 95.9%)  |
|                                     | 15-54    | 544       | 98.9% (98.0%; 99.9%)    | 98.3% (97.0%; 99.6%)   | 97.5% (95.7%; 99.3%)  | 96.0% (92.5%; 99.5%)  |
|                                     | 55-74    | 589       | 93.7% (91.5%; 95.9%)    | 90.1% (87.0%; 93.3%)   | 88.7% (84.8%; 92.8%)  | 87.8% (80.4%; 95.9%)  |
|                                     | 75+      | 198       | 78.8% (72.3%; 85.9%)    | 75.3% (66.4%; 85.5%)   | 74.4% (60.8%; 91.0%)  | 25.6% (6.4%; 102.5%)  |
| Wallonia                            | All ages | 1,034     | 96.0% (94.7%; 97.4%)    | 93.4% (91.4%; 95.4%)   | 92.5% (90.1%; 95.0%)  | 84.0% (77.8%; 90.8%)  |

| Net Survival Probability, 2013-2022 |                 |           |                       |                       |                       |                       |
|-------------------------------------|-----------------|-----------|-----------------------|-----------------------|-----------------------|-----------------------|
| Region                              | Age             | N at risk | 1-y (95%CI)           | 3-y (95%CI)           | 5-y (95%CI)           | 10-y (95%CI)          |
|                                     | <b>15-54</b>    | 439       | 99.5% (98.7%; 100.3%) | 99.2% (98.0%; 100.3%) | 98.1% (96.4%; 99.9%)  | 95.1% (91.1%; 99.3%)  |
|                                     | <b>55-74</b>    | 500       | 96.1% (94.1%; 98.1%)  | 93.4% (90.6%; 96.3%)  | 93.1% (89.5%; 96.7%)  | 83.9% (75.6%; 93.1%)  |
|                                     | <b>75+</b>      | 95        | 79.6% (70.9%; 89.4%)  | 66.9% (55.2%; 81.1%)  | 64.4% (50.3%; 82.3%)  | 34.4% (13.9%; 85.0%)  |
| Females                             |                 |           |                       |                       |                       |                       |
| <b>Belgium</b>                      | <b>All ages</b> | 7,224     | 97.0% (96.5%; 97.4%)  | 96.6% (96.0%; 97.2%)  | 96.1% (95.4%; 96.9%)  | 96.7% (95.2%; 98.2%)  |
|                                     | <b>15-54</b>    | 4,117     | 99.6% (99.4%; 99.8%)  | 99.4% (99.1%; 99.7%)  | 99.3% (98.9%; 99.6%)  | 98.9% (98.1%; 99.6%)  |
|                                     | <b>55-74</b>    | 2,471     | 97.2% (96.4%; 97.9%)  | 96.4% (95.4%; 97.4%)  | 95.8% (94.5%; 97.1%)  | 95.7% (93.3%; 98.2%)  |
|                                     | <b>75+</b>      | 636       | 79.3% (75.8%; 83.0%)  | 79.3% (74.8%; 83.9%)  | 77.4% (71.2%; 84.0%)  | 87.4% (74.0%; 103.3%) |
| Brussels                            | <b>All ages</b> | 1,002     | 98.7% (97.8%; 99.6%)  | 98.3% (97.0%; 99.7%)  | 96.2% (93.8%; 98.6%)  | 95.3% (90.7%; 100.1%) |
|                                     | <b>15-54</b>    | 595       | 99.6% (99.0%; 100.2%) | 99.6% (99.0%; 100.3%) | 99.5% (98.5%; 100.4%) | 99.4% (97.7%; 101.2%) |
|                                     | <b>55-74</b>    | 339       | 98.4% (96.8%; 100.1%) | 97.3% (94.9%; 99.9%)  | 94.3% (90.6%; 98.2%)  | 95.9% (89.7%; 102.5%) |
|                                     | <b>75+</b>      | 68        | 92.6% (84.5%; 101.4%) | 91.4% (78.7%; 106.2%) | 77.4% (56.1%; 106.9%) | 58.3% (29.5%; 115.5%) |
| Flanders                            | <b>All ages</b> | 3,531     | 95.8% (95.0%; 96.5%)  | 95.5% (94.6%; 96.4%)  | 95.3% (94.2%; 96.4%)  | 96.9% (94.9%; 99.0%)  |
|                                     | <b>15-54</b>    | 1,969     | 99.6% (99.3%; 99.9%)  | 99.4% (98.9%; 99.8%)  | 99.2% (98.7%; 99.8%)  | 98.8% (97.6%; 100.0%) |
|                                     | <b>55-74</b>    | 1,177     | 96.0% (94.7%; 97.2%)  | 95.5% (93.9%; 97.1%)  | 95.4% (93.4%; 97.4%)  | 96.4% (92.7%; 100.3%) |
|                                     | <b>75+</b>      | 385       | 75.3% (70.7%; 80.3%)  | 75.8% (70.0%; 82.0%)  | 74.9% (67.4%; 83.1%)  | 91.1% (75.7%; 109.7%) |
| Wallonia                            | <b>All ages</b> | 2,691     | 98.0% (97.3%; 98.6%)  | 97.4% (96.6%; 98.3%)  | 97.3% (96.2%; 98.3%)  | 97.0% (94.6%; 99.4%)  |
|                                     | <b>15-54</b>    | 1,553     | 99.6% (99.2%; 100.0%) | 99.4% (98.9%; 99.9%)  | 99.2% (98.6%; 99.8%)  | 98.7% (97.4%; 99.9%)  |
|                                     | <b>55-74</b>    | 955       | 98.2% (97.2%; 99.2%)  | 97.3% (95.9%; 98.7%)  | 96.8% (95.0%; 98.7%)  | 94.8% (91.1%; 98.8%)  |
|                                     | <b>75+</b>      | 183       | 82.9% (76.9%; 89.3%)  | 81.9% (74.4%; 90.2%)  | 82.9% (72.9%; 94.1%)  | 94.0% (69.8%; 126.5%) |

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

## 4.2. Thyroid cancer survival: by tumour type and tumour stage

### 4.2.1. Thyroid cancer survival by type, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022

| Type                                | cStage | Net Survival Probability, 2013-2022 |                         |                       |                        |                        |                        |                         |
|-------------------------------------|--------|-------------------------------------|-------------------------|-----------------------|------------------------|------------------------|------------------------|-------------------------|
|                                     |        | N at risk                           | 1-y (95%CI)             | 2-y (95%CI)           | 3-y (95%CI)            | 4-y (95%CI)            | 5-y (95%CI)            | 10-y (95%CI)            |
| <b>Total</b>                        |        | 9,906                               | 96.4% (96.0%; 96.8%)    | 95.9% (95.4%; 96.4%)  | 95.5% (94.9%; 96.1%)   | 95.2% (94.5%; 95.8%)   | 94.8% (94.1%; 95.6%)   | 93.9% (92.2%; 95.7%)    |
| <b>Males</b>                        |        |                                     |                         |                       |                        |                        |                        |                         |
| <b>Papillary carcinoma &lt;55y</b>  | All    | 928                                 | 99.7% (99.2%; 100.1%)   | 99.4% (98.8%; 100.1%) | 99.4% (98.7%; 100.2%)  | 99.3% (98.4%; 100.1%)  | 98.8% (97.7%; 99.9%)   | 98.4% (96.3%; 100.5%)   |
|                                     | I      | 421                                 | 99.7% (99.0%; 100.4%)   | 99.7% (98.9%; 100.5%) | 99.6% (98.6%; 100.6%)  | 99.1% (97.6%; 100.5%)  | 98.4% (96.5%; 100.3%)  | 99.6% (97.6%; 101.5%)   |
|                                     | II     | 20                                  | N<50                    | N<50                  | N<50                   | N<50                   | N<50                   | N<50                    |
|                                     | III    | 7                                   | N<50                    | N<50                  | N<50                   | N<50                   | N<50                   | N<50                    |
|                                     | IV     | 6                                   | N<50                    | N<50                  | N<50                   | N<50                   | N<50                   | N<50                    |
|                                     | X/NA   | 474                                 | 99.6% (98.9%; 100.3%)   | 99.6% (98.8%; 100.4%) | 99.6% (98.7%; 100.6%)  | 99.6% (98.6%; 100.7%)  | 99.1% (97.8%; 100.5%)  | 97.8% (95.0%; 100.8%)   |
| <b>Papillary carcinoma 55+y</b>     | All    | 1,045                               | 97.9% (96.6%; 99.2%)    | 97.5% (95.8%; 99.2%)  | 95.9% (93.8%; 98.2%)   | 94.4% (91.7%; 97.2%)   | 94.9% (91.9%; 97.9%)   | 85.6% (75.3%; 97.4%)    |
|                                     | I      | 256                                 | 99.2% (97.1%; 101.5%)   | 97.4% (94.0%; 100.9%) | 97.0% (92.6%; 101.6%)  | 98.1% (92.7%; 103.7%)  | 98.3% (91.6%; 105.4%)  | 106.3% (89.6%; 126.0%)  |
|                                     | II     | 103                                 | 98.0% (94.1%; 102.0%)   | 98.9% (94.6%; 103.5%) | 101.2% (96.7%; 105.8%) | 103.7% (99.2%; 108.5%) | 104.2% (98.2%; 110.7%) | 119.4% (105.8%; 134.8%) |
|                                     | III    | 26                                  | N<50                    | N<50                  | N<50                   | N<50                   | N<50                   | N<50                    |
|                                     | IV     | 52                                  | 85.4% (75.4%; 96.8%)    | 78.0% (65.9%; 92.2%)  | 74.0% (60.8%; 90.2%)   | 65.8% (51.0%; 84.9%)   | 57.5% (42.2%; 78.4%)   | 46.0% (27.2%; 77.9%)    |
|                                     | X/NA   | 608                                 | 98.5% (97.0%; 100.1%)   | 99.1% (97.2%; 101.0%) | 96.7% (94.0%; 99.5%)   | 94.9% (91.6%; 98.3%)   | 96.1% (92.5%; 99.8%)   | 85.3% (73.1%; 99.5%)    |
| <b>Follicular carcinoma &lt;55y</b> | All    | 133                                 | 100.2% (100.2%; 100.2%) | 98.9% (96.9%; 101.1%) | 99.2% (97.1%; 101.3%)  | 99.5% (97.4%; 101.6%)  | 98.7% (95.8%; 101.8%)  | 92.4% (83.6%; 102.2%)   |
|                                     | I      | 72                                  | 100.2% (100.2%; 100.2%) | 99.0% (96.3%; 101.8%) | 99.2% (96.6%; 102.0%)  | 99.5% (96.8%; 102.2%)  | 99.7% (97.0%; 102.5%)  | 98.0% (91.8%; 104.7%)   |
|                                     | II     | 1                                   | N<50                    | N<50                  | N<50                   | N<50                   | N<50                   | N<50                    |
|                                     | III    | 5                                   | N<50                    | N<50                  | N<50                   | N<50                   | N<50                   | N<50                    |
|                                     | X/NA   | 55                                  | 100.3% (100.3%; 100.3%) | 98.6% (95.0%; 102.4%) | 98.9% (95.3%; 102.7%)  | 99.3% (95.6%; 103.1%)  | 97.3% (91.7%; 103.2%)  | 90.4% (77.3%; 105.7%)   |
| <b>Follicular carcinoma 55+y</b>    | All    | 256                                 | 97.6% (94.8%; 100.5%)   | 95.9% (91.9%; 100.1%) | 94.1% (88.8%; 99.6%)   | 92.1% (85.8%; 98.8%)   | 94.3% (87.3%; 101.9%)  | 86.3% (67.6%; 110.3%)   |



| Net Survival Probability, 2013-2022 |        |           |                       |                       |                       |                       |                        |                         |
|-------------------------------------|--------|-----------|-----------------------|-----------------------|-----------------------|-----------------------|------------------------|-------------------------|
| Type                                | cStage | N at risk | 1-y (95%CI)           | 2-y (95%CI)           | 3-y (95%CI)           | 4-y (95%CI)           | 5-y (95%CI)            | 10-y (95%CI)            |
|                                     | I      | 55        | 98.7% (93.8%; 103.9%) | 93.5% (85.1%; 102.7%) | 90.5% (79.5%; 103.0%) | 93.6% (82.3%; 106.6%) | 97.1% (85.3%; 110.5%)  | 132.1% (116.1%; 150.4%) |
|                                     | II     | 43        | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | III    | 6         | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | IV     | 31        | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | X/NA   | 121       | 98.2% (94.2%; 102.2%) | 97.2% (91.7%; 103.1%) | 96.8% (89.7%; 104.5%) | 98.7% (90.8%; 107.3%) | 102.5% (93.7%; 112.1%) | 96.5% (71.4%; 130.4%)   |
| <b>Medullary carcinoma</b>          | All    | 138       | 97.6% (94.1%; 101.2%) | 91.6% (85.9%; 97.7%)  | 89.7% (83.1%; 96.8%)  | 91.6% (84.5%; 99.2%)  | 85.9% (74.5%; 99.0%)   | 81.4% (63.8%; 103.8%)   |
|                                     | I      | 16        | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | II     | 17        | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | III    | 19        | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | IV     | 42        | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | X/NA   | 44        | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
| <b>Anaplastic carcinoma</b>         | All    | 79        | 30.7% (21.9%; 43.1%)  | 25.5% (17.2%; 37.8%)  | 16.2% (9.0%; 29.0%)   | 14.5% (7.6%; 27.6%)   | 10.5% (4.4%; 25.5%)    | FU<10y                  |
| <b>Other</b>                        | All    | 106       | 54.2% (45.3%; 64.9%)  | 48.5% (39.4%; 59.6%)  | 44.5% (35.1%; 56.3%)  | 42.5% (32.7%; 55.2%)  | 38.8% (28.7%; 52.4%)   | 36.5% (23.0%; 57.8%)    |
|                                     | I      | 6         | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | II     | 18        | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | III    | 5         | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | IV     | 28        | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | X/NA   | 49        | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
| <b>Females</b>                      |        |           |                       |                       |                       |                       |                        |                         |
| <b>Papillary carcinoma &lt;55y</b>  | All    | 3,611     | 99.8% (99.6%; 100.0%) | 99.7% (99.5%; 99.9%)  | 99.7% (99.4%; 100.0%) | 99.5% (99.1%; 99.8%)  | 99.6% (99.2%; 99.9%)   | 99.3% (98.5%; 100.1%)   |
|                                     | I      | 1,769     | 99.8% (99.6%; 100.1%) | 99.8% (99.4%; 100.1%) | 99.7% (99.4%; 100.1%) | 99.5% (99.0%; 100.0%) | 99.5% (98.9%; 100.0%)  | 99.8% (98.8%; 100.7%)   |
|                                     | II     | 32        | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | III    | 18        | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | IV     | 4         | N<50                  | N<50                  | N<50                  | N<50                  | N<50                   | N<50                    |

| Net Survival Probability, 2013-2022 |        |           |                         |                         |                         |                         |                         |                        |
|-------------------------------------|--------|-----------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|------------------------|
| Type                                | cStage | N at risk | 1-y (95%CI)             | 2-y (95%CI)             | 3-y (95%CI)             | 4-y (95%CI)             | 5-y (95%CI)             | 10-y (95%CI)           |
|                                     | X/NA   | 1,788     | 99.8% (99.5%; 100.1%)   | 99.7% (99.3%; 100.0%)   | 99.7% (99.3%; 100.1%)   | 99.6% (99.1%; 100.1%)   | 99.8% (99.3%; 100.2%)   | 99.2% (98.2%; 100.3%)  |
| <b>Papillary carcinoma 55+y</b>     | All    | 2,372     | 98.8% (98.2%; 99.5%)    | 98.8% (98.0%; 99.7%)    | 99.1% (98.1%; 100.2%)   | 99.5% (98.3%; 100.7%)   | 99.1% (97.7%; 100.6%)   | 102.4% (98.8%; 106.1%) |
|                                     | I      | 628       | 101.0% (100.5%; 101.4%) | 101.1% (100.0%; 102.2%) | 101.8% (100.4%; 103.3%) | 103.0% (101.2%; 104.8%) | 104.6% (102.5%; 106.8%) | 111.2% (99.4%; 124.3%) |
|                                     | II     | 150       | 97.3% (93.7%; 101.0%)   | 98.8% (94.8%; 102.9%)   | 99.0% (94.1%; 104.2%)   | 99.2% (93.6%; 105.1%)   | 99.9% (93.6%; 106.7%)   | 101.1% (77.4%; 132.1%) |
|                                     | III    | 40        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                   |
|                                     | IV     | 65        | 75.0% (64.6%; 87.0%)    | 67.4% (55.8%; 81.4%)    | 60.6% (48.2%; 76.2%)    | 58.6% (45.4%; 75.6%)    | 59.6% (45.7%; 77.8%)    | 63.4% (43.4%; 92.8%)   |
|                                     | X/NA   | 1,489     | 99.2% (98.5%; 100.0%)   | 99.5% (98.6%; 100.4%)   | 99.9% (98.8%; 101.0%)   | 100.4% (99.0%; 101.7%)  | 99.3% (97.6%; 101.0%)   | 102.3% (98.6%; 106.1%) |
| <b>Follicular carcinoma &lt;55y</b> | All    | 374       | 99.6% (98.8%; 100.3%)   | 99.7% (99.0%; 100.5%)   | 99.0% (97.7%; 100.2%)   | 99.1% (97.9%; 100.4%)   | 98.5% (96.9%; 100.2%)   | 97.4% (94.3%; 100.5%)  |
|                                     | I      | 179       | 99.0% (97.5%; 100.5%)   | 99.1% (97.6%; 100.7%)   | 99.2% (97.7%; 100.8%)   | 99.4% (97.8%; 100.9%)   | 99.5% (98.0%; 101.0%)   | 95.5% (89.0%; 102.4%)  |
|                                     | II     | 20        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                   |
|                                     | III    | 2         | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                   |
|                                     | IV     | 1         | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                   |
|                                     | X/NA   | 172       | 100.1% (100.1%; 100.1%) | 100.3% (100.3%; 100.3%) | 98.5% (96.4%; 100.7%)   | 98.7% (96.6%; 100.8%)   | 98.1% (95.5%; 100.7%)   | 99.3% (96.8%; 102.0%)  |
| <b>Follicular carcinoma 55+y</b>    | All    | 374       | 96.1% (93.5%; 98.7%)    | 95.6% (92.4%; 98.9%)    | 95.6% (91.8%; 99.5%)    | 93.0% (88.1%; 98.3%)    | 89.5% (83.0%; 96.6%)    | 90.5% (80.0%; 102.3%)  |
|                                     | I      | 70        | 100.3% (97.3%; 103.4%)  | 100.8% (96.6%; 105.1%)  | 101.1% (95.8%; 106.7%)  | 100.3% (93.2%; 107.9%)  | 94.1% (82.3%; 107.6%)   | 111.0% (97.1%; 126.9%) |
|                                     | II     | 48        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                   |
|                                     | III    | 18        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                   |
|                                     | IV     | 49        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                   |
|                                     | X/NA   | 189       | 99.7% (97.4%; 102.1%)   | 101.2% (98.3%; 104.2%)  | 101.3% (97.3%; 105.5%)  | 97.3% (90.8%; 104.2%)   | 97.7% (90.6%; 105.3%)   | 101.3% (88.7%; 115.8%) |
| <b>Medullary carcinoma</b>          | All    | 203       | 97.7% (95.1%; 100.3%)   | 95.7% (92.2%; 99.3%)    | 95.2% (91.2%; 99.3%)    | 95.0% (90.5%; 99.8%)    | 95.0% (89.9%; 100.4%)   | 90.2% (78.5%; 103.7%)  |
|                                     | I      | 45        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                   |
|                                     | II     | 17        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                   |
|                                     | III    | 5         | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                   |
|                                     | IV     | 36        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                   |

| Type                        | cStage | N<br>at risk | Net Survival Probability, 2013-2022 |                       |                       |                       |                        |                       |
|-----------------------------|--------|--------------|-------------------------------------|-----------------------|-----------------------|-----------------------|------------------------|-----------------------|
|                             |        |              | 1-y (95%CI)                         | 2-y (95%CI)           | 3-y (95%CI)           | 4-y (95%CI)           | 5-y (95%CI)            | 10-y (95%CI)          |
|                             | X/NA   | 100          | 98.1% (94.8%; 101.6%)               | 98.4% (94.5%; 102.5%) | 98.7% (94.2%; 103.4%) | 99.1% (94.0%; 104.6%) | 101.3% (96.0%; 106.8%) | 97.2% (82.7%; 114.2%) |
| <b>Anaplastic carcinoma</b> | All    | 104          | 15.9% (10.2%; 24.8%)                | 10.4% (5.7%; 18.8%)   | 9.3% (4.9%; 17.6%)    | 8.2% (4.1%; 16.3%)    | 8.3% (4.2%; 16.6%)     | 8.5% (3.9%; 18.6%)    |
| <b>Other</b>                | All    | 192          | 61.6% (54.9%; 69.1%)                | 56.0% (49.0%; 63.9%)  | 52.2% (45.0%; 60.6%)  | 51.7% (44.3%; 60.5%)  | 50.2% (42.0%; 59.9%)   | 37.9% (27.0%; 53.2%)  |
|                             | I      | 23           | N<50                                | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |
|                             | II     | 9            | N<50                                | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |
|                             | III    | 3            | N<50                                | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |
|                             | IV     | 51           | 30.8% (20.4%; 46.5%)                | 22.5% (13.2%; 38.2%)  | 20.6% (11.5%; 36.7%)  | 21.7% (12.2%; 38.7%)  | 23.4% (13.1%; 41.7%)   | FU<10y                |
|                             | X/NA   | 106          | 67.1% (58.4%; 77.0%)                | 61.4% (52.3%; 72.0%)  | 56.5% (47.0%; 67.8%)  | 56.3% (46.5%; 68.0%)  | 52.9% (42.2%; 66.3%)   | 44.4% (31.0%; 63.6%)  |

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2.2. Thyroid cancer survival by type, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2013-2022

| Type                                | pStage | Net Survival Probability, 2013-2022 |                         |                         |                        |                        |                        |                         |  |
|-------------------------------------|--------|-------------------------------------|-------------------------|-------------------------|------------------------|------------------------|------------------------|-------------------------|--|
|                                     |        | N at risk                           | 1-y (95%CI)             | 2-y (95%CI)             | 3-y (95%CI)            | 4-y (95%CI)            | 5-y (95%CI)            | 10-y (95%CI)            |  |
| <b>Total</b>                        |        | 9,906                               | 96.4% (96.0%; 96.8%)    | 95.9% (95.4%; 96.4%)    | 95.5% (94.9%; 96.1%)   | 95.2% (94.5%; 95.8%)   | 94.8% (94.1%; 95.6%)   | 93.9% (92.2%; 95.7%)    |  |
| <b>Males</b>                        |        |                                     |                         |                         |                        |                        |                        |                         |  |
| <b>Papillary carcinoma &lt;55y</b>  | All    | 928                                 | 99.7% (99.2%; 100.1%)   | 99.4% (98.8%; 100.1%)   | 99.4% (98.7%; 100.2%)  | 99.3% (98.4%; 100.1%)  | 98.8% (97.7%; 99.9%)   | 98.4% (96.3%; 100.5%)   |  |
|                                     | I      | 817                                 | 99.6% (99.0%; 100.1%)   | 99.4% (98.7%; 100.1%)   | 99.3% (98.5%; 100.1%)  | 99.2% (98.3%; 100.2%)  | 98.7% (97.6%; 99.9%)   | 98.4% (96.1%; 100.8%)   |  |
|                                     | II     | 23                                  | N<50                    | N<50                    | N<50                   | N<50                   | N<50                   | N<50                    |  |
|                                     | III    | 26                                  | N<50                    | N<50                    | N<50                   | N<50                   | N<50                   | N<50                    |  |
|                                     | IV     | 22                                  | N<50                    | N<50                    | N<50                   | N<50                   | N<50                   | N<50                    |  |
|                                     | X/NA   | 40                                  | N<50                    | N<50                    | N<50                   | N<50                   | N<50                   | N<50                    |  |
| <b>Papillary carcinoma 55+y</b>     | All    | 1,045                               | 97.9% (96.6%; 99.2%)    | 97.5% (95.8%; 99.2%)    | 95.9% (93.8%; 98.2%)   | 94.4% (91.7%; 97.2%)   | 94.9% (91.9%; 97.9%)   | 85.6% (75.3%; 97.4%)    |  |
|                                     | I      | 639                                 | 100.5% (99.5%; 101.5%)  | 101.6% (100.3%; 103.0%) | 100.7% (98.5%; 102.9%) | 100.5% (97.7%; 103.4%) | 102.0% (98.8%; 105.2%) | 91.6% (76.4%; 109.9%)   |  |
|                                     | II     | 178                                 | 99.9% (97.6%; 102.2%)   | 97.9% (94.1%; 101.8%)   | 98.0% (93.3%; 102.9%)  | 95.0% (88.7%; 101.7%)  | 96.7% (89.9%; 103.9%)  | 114.6% (102.9%; 127.6%) |  |
|                                     | III    | 91                                  | 99.3% (95.7%; 103.2%)   | 99.1% (93.9%; 104.5%)   | 94.7% (86.8%; 103.3%)  | 92.8% (83.6%; 103.0%)  | 91.1% (80.9%; 102.7%)  | 70.8% (51.0%; 98.2%)    |  |
|                                     | IV     | 49                                  | N<50                    | N<50                    | N<50                   | N<50                   | N<50                   | N<50                    |  |
|                                     | X/NA   | 88                                  | 74.1% (64.8%; 84.6%)    | 68.7% (58.5%; 80.7%)    | 64.1% (53.0%; 77.5%)   | 59.0% (47.2%; 73.6%)   | 57.7% (45.7%; 72.8%)   | 60.4% (44.2%; 82.4%)    |  |
| <b>Follicular carcinoma &lt;55y</b> | All    | 133                                 | 100.2% (100.2%; 100.2%) | 98.9% (96.9%; 101.1%)   | 99.2% (97.1%; 101.3%)  | 99.5% (97.4%; 101.6%)  | 98.7% (95.8%; 101.8%)  | 92.4% (83.6%; 102.2%)   |  |
|                                     | I      | 100                                 | 100.2% (100.2%; 100.2%) | 99.4% (97.5%; 101.4%)   | 99.6% (97.7%; 101.6%)  | 99.9% (97.9%; 101.9%)  | 100.1% (98.2%; 102.1%) | 99.5% (95.3%; 103.8%)   |  |
|                                     | II     | 7                                   | N<50                    | N<50                    | N<50                   | N<50                   | N<50                   | N<50                    |  |
|                                     | III    | 9                                   | N<50                    | N<50                    | N<50                   | N<50                   | N<50                   | N<50                    |  |
|                                     | IV     | 1                                   | N<50                    | N<50                    | N<50                   | N<50                   | N<50                   | N<50                    |  |
|                                     | X/NA   | 16                                  | N<50                    | N<50                    | N<50                   | N<50                   | N<50                   | N<50                    |  |
| <b>Follicular carcinoma 55+y</b>    | All    | 256                                 | 97.6% (94.8%; 100.5%)   | 95.9% (91.9%; 100.1%)   | 94.1% (88.8%; 99.6%)   | 92.1% (85.8%; 98.8%)   | 94.3% (87.3%; 101.9%)  | 86.3% (67.6%; 110.3%)   |  |
|                                     | I      | 71                                  | 97.9% (93.2%; 102.8%)   | 95.9% (89.3%; 102.9%)   | 94.6% (86.3%; 103.7%)  | 97.5% (89.0%; 106.9%)  | 97.1% (86.6%; 108.8%)  | 101.4% (79.1%; 129.9%)  |  |

| Net Survival Probability, 2013-2022 |        |           |                         |                         |                         |                       |                       |                        |  |
|-------------------------------------|--------|-----------|-------------------------|-------------------------|-------------------------|-----------------------|-----------------------|------------------------|--|
| Type                                | pStage | N at risk | 1-y (95%CI)             | 2-y (95%CI)             | 3-y (95%CI)             | 4-y (95%CI)           | 5-y (95%CI)           | 10-y (95%CI)           |  |
|                                     | II     | 94        | 100.3% (96.7%; 104.1%)  | 100.9% (95.7%; 106.5%)  | 97.2% (88.7%; 106.4%)   | 96.4% (86.4%; 107.5%) | 99.9% (89.6%; 111.4%) | 100.7% (79.3%; 127.8%) |  |
|                                     | III    | 34        | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
|                                     | IV     | 18        | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
|                                     | X/NA   | 39        | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
| <b>Medullary carcinoma</b>          | All    | 138       | 97.6% (94.1%; 101.2%)   | 91.6% (85.9%; 97.7%)    | 89.7% (83.1%; 96.8%)    | 91.6% (84.5%; 99.2%)  | 85.9% (74.5%; 99.0%)  | 81.4% (63.8%; 103.8%)  |  |
|                                     | I      | 32        | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
|                                     | II     | 24        | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
|                                     | III    | 23        | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
|                                     | IV     | 44        | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
|                                     | X/NA   | 15        | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
| <b>Anaplastic carcinoma</b>         | All    | 79        | 30.7% (21.9%; 43.1%)    | 25.5% (17.2%; 37.8%)    | 16.2% (9.0%; 29.0%)     | 14.5% (7.6%; 27.6%)   | 10.5% (4.4%; 25.5%)   | FU<10y                 |  |
| <b>Other</b>                        | All    | 106       | 54.2% (45.3%; 64.9%)    | 48.5% (39.4%; 59.6%)    | 44.5% (35.1%; 56.3%)    | 42.5% (32.7%; 55.2%)  | 38.8% (28.7%; 52.4%)  | 36.5% (23.0%; 57.8%)   |  |
|                                     | I      | 10        | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
|                                     | II     | 14        | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
|                                     | III    | 8         | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
|                                     | IV     | 12        | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
|                                     | X/NA   | 62        | 35.1% (25.0%; 49.5%)    | 29.6% (19.8%; 44.2%)    | 26.3% (16.7%; 41.4%)    | 24.8% (15.1%; 40.7%)  | 26.3% (16.0%; 43.1%)  | FU<10y                 |  |
| <b>Females</b>                      |        |           |                         |                         |                         |                       |                       |                        |  |
| <b>Papillary carcinoma &lt;55y</b>  | All    | 3,611     | 99.8% (99.6%; 100.0%)   | 99.7% (99.5%; 99.9%)    | 99.7% (99.4%; 100.0%)   | 99.5% (99.1%; 99.8%)  | 99.6% (99.2%; 99.9%)  | 99.3% (98.5%; 100.1%)  |  |
|                                     | I      | 3,301     | 99.8% (99.7%; 100.0%)   | 99.8% (99.5%; 100.0%)   | 99.8% (99.5%; 100.0%)   | 99.6% (99.2%; 99.9%)  | 99.6% (99.2%; 100.0%) | 99.3% (98.5%; 100.2%)  |  |
|                                     | II     | 57        | 100.2% (100.2%; 100.2%) | 100.5% (100.5%; 100.5%) | 100.7% (100.7%; 100.7%) | 99.1% (95.6%; 102.8%) | 99.4% (95.8%; 103.1%) | 101.3% (97.7%; 105.0%) |  |
|                                     | III    | 80        | 100.2% (100.2%; 100.2%) | 99.2% (96.8%; 101.7%)   | 99.4% (97.0%; 101.9%)   | 98.4% (95.0%; 102.0%) | 98.7% (95.3%; 102.2%) | 97.1% (91.4%; 103.2%)  |  |
|                                     | IV     | 17        | N<50                    | N<50                    | N<50                    | N<50                  | N<50                  | N<50                   |  |
|                                     | X/NA   | 156       | 98.2% (96.0%; 100.4%)   | 98.3% (96.2%; 100.5%)   | 98.5% (96.3%; 100.7%)   | 98.6% (96.5%; 100.8%) | 98.8% (96.6%; 101.0%) | 97.7% (94.0%; 101.6%)  |  |

| Type                                | pStage | N<br>at risk | Net Survival Probability, 2013-2022 |                         |                         |                         |                         |                         |
|-------------------------------------|--------|--------------|-------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                     |        |              | 1-y (95%CI)                         | 2-y (95%CI)             | 3-y (95%CI)             | 4-y (95%CI)             | 5-y (95%CI)             | 10-y (95%CI)            |
| <b>Papillary carcinoma 55+y</b>     | All    | 2,372        | 98.8% (98.2%; 99.5%)                | 98.8% (98.0%; 99.7%)    | 99.1% (98.1%; 100.2%)   | 99.5% (98.3%; 100.7%)   | 99.1% (97.7%; 100.6%)   | 102.4% (98.8%; 106.1%)  |
|                                     | I      | 1,658        | 100.3% (99.9%; 100.8%)              | 100.7% (100.0%; 101.4%) | 101.7% (100.9%; 102.5%) | 102.3% (101.3%; 103.3%) | 102.4% (101.1%; 103.8%) | 107.3% (103.6%; 111.2%) |
|                                     | II     | 316          | 98.2% (96.3%; 100.2%)               | 98.3% (95.9%; 100.8%)   | 97.6% (94.5%; 100.7%)   | 96.7% (92.9%; 100.6%)   | 96.0% (91.7%; 100.6%)   | 93.5% (80.7%; 108.4%)   |
|                                     | III    | 184          | 98.7% (96.1%; 101.4%)               | 99.4% (96.1%; 102.7%)   | 99.4% (95.5%; 103.6%)   | 102.0% (97.7%; 106.4%)  | 100.3% (94.5%; 106.4%)  | 100.0% (88.2%; 113.3%)  |
|                                     | IV     | 65           | 93.3% (86.5%; 100.8%)               | 87.6% (78.3%; 97.9%)    | 80.5% (69.4%; 93.5%)    | 72.9% (60.4%; 88.0%)    | 73.3% (60.3%; 89.1%)    | 70.8% (53.2%; 94.2%)    |
|                                     | X/NA   | 149          | 86.2% (80.2%; 92.6%)                | 83.6% (76.7%; 91.1%)    | 82.6% (75.0%; 91.0%)    | 83.4% (75.3%; 92.3%)    | 80.2% (71.1%; 90.5%)    | 87.4% (72.1%; 105.9%)   |
| <b>Follicular carcinoma &lt;55y</b> | All    | 374          | 99.6% (98.8%; 100.3%)               | 99.7% (99.0%; 100.5%)   | 99.0% (97.7%; 100.2%)   | 99.1% (97.9%; 100.4%)   | 98.5% (96.9%; 100.2%)   | 97.4% (94.3%; 100.5%)   |
|                                     | I      | 285          | 99.8% (99.1%; 100.4%)               | 99.9% (99.2%; 100.6%)   | 99.6% (98.6%; 100.6%)   | 99.7% (98.7%; 100.8%)   | 99.3% (97.8%; 100.8%)   | 97.7% (94.0%; 101.5%)   |
|                                     | II     | 31           | N<50                                | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | III    | 11           | N<50                                | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | IV     | 3            | N<50                                | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | X/NA   | 44           | N<50                                | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
| <b>Follicular carcinoma 55+y</b>    | All    | 374          | 96.1% (93.5%; 98.7%)                | 95.6% (92.4%; 98.9%)    | 95.6% (91.8%; 99.5%)    | 93.0% (88.1%; 98.3%)    | 89.5% (83.0%; 96.6%)    | 90.5% (80.0%; 102.3%)   |
|                                     | I      | 134          | 100.3% (98.2%; 102.5%)              | 101.6% (99.0%; 104.4%)  | 103.2% (100.0%; 106.5%) | 100.5% (94.7%; 106.7%)  | 98.5% (90.9%; 106.9%)   | 99.3% (82.0%; 120.3%)   |
|                                     | II     | 108          | 99.6% (95.9%; 103.5%)               | 100.7% (95.8%; 105.9%)  | 103.5% (97.4%; 109.9%)  | 100.4% (90.6%; 111.4%)  | 105.7% (95.3%; 117.3%)  | 112.1% (90.0%; 139.7%)  |
|                                     | III    | 45           | N<50                                | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | IV     | 32           | N<50                                | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | X/NA   | 55           | 86.5% (76.9%; 97.2%)                | 75.9% (63.9%; 90.1%)    | 68.4% (55.3%; 84.6%)    | 70.4% (56.9%; 87.1%)    | 62.3% (47.5%; 81.6%)    | 65.3% (43.7%; 97.6%)    |
| <b>Medullary carcinoma</b>          | All    | 203          | 97.7% (95.1%; 100.3%)               | 95.7% (92.2%; 99.3%)    | 95.2% (91.2%; 99.3%)    | 95.0% (90.5%; 99.8%)    | 95.0% (89.9%; 100.4%)   | 90.2% (78.5%; 103.7%)   |
|                                     | I      | 89           | 101.0% (101.0%; 101.0%)             | 102.1% (102.1%; 102.1%) | 103.4% (103.4%; 103.4%) | 104.8% (104.8%; 104.8%) | 106.4% (106.4%; 106.4%) | 115.9% (103.1%; 130.3%) |
|                                     | II     | 30           | N<50                                | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | III    | 22           | N<50                                | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | IV     | 43           | N<50                                | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | X/NA   | 19           | N<50                                | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |

| Net Survival Probability, 2013-2022 |        |           |                      |                      |                      |                      |                      |                      |
|-------------------------------------|--------|-----------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Type                                | pStage | N at risk | 1-y (95%CI)          | 2-y (95%CI)          | 3-y (95%CI)          | 4-y (95%CI)          | 5-y (95%CI)          | 10-y (95%CI)         |
| <b>Anaplastic carcinoma</b>         | All    | 104       | 15.9% (10.2%; 24.8%) | 10.4% (5.7%; 18.8%)  | 9.3% (4.9%; 17.6%)   | 8.2% (4.1%; 16.3%)   | 8.3% (4.2%; 16.6%)   | 8.5% (3.9%; 18.6%)   |
| <b>Other</b>                        | All    | 192       | 61.6% (54.9%; 69.1%) | 56.0% (49.0%; 63.9%) | 52.2% (45.0%; 60.6%) | 51.7% (44.3%; 60.5%) | 50.2% (42.0%; 59.9%) | 37.9% (27.0%; 53.2%) |
|                                     | I      | 35        | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 |
|                                     | II     | 19        | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 |
|                                     | III    | 1         | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 |
|                                     | IV     | 26        | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 |
|                                     | X/NA   | 111       | 51.7% (43.0%; 62.3%) | 43.4% (34.7%; 54.2%) | 37.5% (28.9%; 48.7%) | 37.0% (28.2%; 48.5%) | 34.7% (25.2%; 47.8%) | 29.9% (20.0%; 44.7%) |

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2.3. Thyroid cancer survival by type, stage and sex: number at risk and net survival probabilities, 2013-2022

| Net Survival Probability, 2013-2022 |       |           |                         |                        |                       |                       |                        |                         |
|-------------------------------------|-------|-----------|-------------------------|------------------------|-----------------------|-----------------------|------------------------|-------------------------|
| Type                                | Stage | N at risk | 1-y (95%CI)             | 2-y (95%CI)            | 3-y (95%CI)           | 4-y (95%CI)           | 5-y (95%CI)            | 10-y (95%CI)            |
| <b>Total</b>                        |       | 9,906     | 96.4% (96.0%; 96.8%)    | 95.9% (95.4%; 96.4%)   | 95.5% (94.9%; 96.1%)  | 95.2% (94.5%; 95.8%)  | 94.8% (94.1%; 95.6%)   | 93.9% (92.2%; 95.7%)    |
| <b>Males</b>                        |       |           |                         |                        |                       |                       |                        |                         |
| <b>Papillary carcinoma &lt;55y</b>  | All   | 928       | 99.7% (99.2%; 100.1%)   | 99.4% (98.8%; 100.1%)  | 99.4% (98.7%; 100.2%) | 99.3% (98.4%; 100.1%) | 98.8% (97.7%; 99.9%)   | 98.4% (96.3%; 100.5%)   |
|                                     | I     | 816       | 99.6% (99.0%; 100.1%)   | 99.5% (98.9%; 100.2%)  | 99.5% (98.7%; 100.2%) | 99.4% (98.5%; 100.3%) | 98.9% (97.7%; 100.0%)  | 98.5% (96.3%; 100.9%)   |
|                                     | II    | 33        | N<50                    | N<50                   | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | III   | 26        | N<50                    | N<50                   | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | IV    | 23        | N<50                    | N<50                   | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | X/NA  | 30        | N<50                    | N<50                   | N<50                  | N<50                  | N<50                   | N<50                    |
| <b>Papillary carcinoma 55+y</b>     | All   | 1,045     | 97.9% (96.6%; 99.2%)    | 97.5% (95.8%; 99.2%)   | 95.9% (93.8%; 98.2%)  | 94.4% (91.7%; 97.2%)  | 94.9% (91.9%; 97.9%)   | 85.6% (75.3%; 97.4%)    |
|                                     | I     | 650       | 100.0% (98.8%; 101.1%)  | 100.6% (99.0%; 102.2%) | 99.7% (97.4%; 102.0%) | 99.2% (96.2%; 102.2%) | 100.9% (97.7%; 104.3%) | 90.9% (75.9%; 108.9%)   |
|                                     | II    | 172       | 99.8% (97.4%; 102.2%)   | 98.3% (94.5%; 102.2%)  | 99.7% (95.4%; 104.3%) | 96.6% (90.5%; 103.2%) | 98.4% (91.7%; 105.5%)  | 116.6% (104.9%; 129.6%) |
|                                     | III   | 93        | 97.3% (92.7%; 102.2%)   | 95.7% (89.4%; 102.5%)  | 91.4% (83.0%; 100.7%) | 89.5% (79.9%; 100.1%) | 87.8% (77.4%; 99.7%)   | 68.3% (49.1%; 95.0%)    |
|                                     | IV    | 74        | 89.1% (81.4%; 97.5%)    | 84.5% (75.1%; 95.0%)   | 77.9% (67.1%; 90.4%)  | 73.2% (61.1%; 87.6%)  | 67.2% (54.4%; 83.0%)   | 47.5% (29.0%; 77.6%)    |
|                                     | X/NA  | 56        | 80.8% (70.3%; 92.8%)    | 79.3% (67.8%; 92.7%)   | 73.4% (60.2%; 89.4%)  | 70.5% (56.8%; 87.7%)  | 70.3% (56.1%; 88.1%)   | 70.9% (50.7%; 99.1%)    |
| <b>Follicular carcinoma &lt;55y</b> | All   | 133       | 100.2% (100.2%; 100.2%) | 98.9% (96.9%; 101.1%)  | 99.2% (97.1%; 101.3%) | 99.5% (97.4%; 101.6%) | 98.7% (95.8%; 101.8%)  | 92.4% (83.6%; 102.2%)   |
|                                     | I     | 101       | 100.2% (100.2%; 100.2%) | 99.4% (97.5%; 101.4%)  | 99.6% (97.7%; 101.6%) | 99.9% (98.0%; 101.8%) | 100.1% (98.2%; 102.1%) | 99.5% (95.4%; 103.8%)   |
|                                     | II    | 7         | N<50                    | N<50                   | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | III   | 10        | N<50                    | N<50                   | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | IV    | 1         | N<50                    | N<50                   | N<50                  | N<50                  | N<50                   | N<50                    |
|                                     | X/NA  | 14        | N<50                    | N<50                   | N<50                  | N<50                  | N<50                   | N<50                    |
| <b>Follicular carcinoma 55+y</b>    | All   | 256       | 97.6% (94.8%; 100.5%)   | 95.9% (91.9%; 100.1%)  | 94.1% (88.8%; 99.6%)  | 92.1% (85.8%; 98.8%)  | 94.3% (87.3%; 101.9%)  | 86.3% (67.6%; 110.3%)   |
|                                     | I     | 75        | 96.8% (91.7%; 102.2%)   | 93.6% (86.5%; 101.2%)  | 92.4% (83.8%; 101.9%) | 95.2% (86.4%; 104.9%) | 98.2% (89.1%; 108.2%)  | 102.5% (80.6%; 130.5%)  |



| Net Survival Probability, 2013-2022 |       |           |                         |                       |                       |                       |                        |                       |  |
|-------------------------------------|-------|-----------|-------------------------|-----------------------|-----------------------|-----------------------|------------------------|-----------------------|--|
| Type                                | Stage | N at risk | 1-y (95%CI)             | 2-y (95%CI)           | 3-y (95%CI)           | 4-y (95%CI)           | 5-y (95%CI)            | 10-y (95%CI)          |  |
|                                     | II    | 90        | 98.7% (94.3%; 103.2%)   | 98.7% (92.9%; 105.0%) | 96.0% (87.5%; 105.3%) | 94.3% (84.2%; 105.6%) | 97.5% (87.1%; 109.2%)  | 98.3% (77.3%; 125.1%) |  |
|                                     | III   | 30        | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
|                                     | IV    | 37        | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
|                                     | X/NA  | 24        | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
| <b>Medullary carcinoma</b>          | All   | 138       | 97.6% (94.1%; 101.2%)   | 91.6% (85.9%; 97.7%)  | 89.7% (83.1%; 96.8%)  | 91.6% (84.5%; 99.2%)  | 85.9% (74.5%; 99.0%)   | 81.4% (63.8%; 103.8%) |  |
|                                     | I     | 32        | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
|                                     | II    | 24        | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
|                                     | III   | 21        | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
|                                     | IV    | 57        | 93.5% (86.1%; 101.6%)   | 78.5% (67.2%; 91.8%)  | 76.8% (64.5%; 91.4%)  | 79.1% (66.5%; 94.1%)  | 75.4% (61.1%; 93.0%)   | 82.3% (52.5%; 129.0%) |  |
|                                     | X/NA  | 4         | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
| <b>Anaplastic carcinoma</b>         | All   | 79        | 30.7% (21.9%; 43.1%)    | 25.5% (17.2%; 37.8%)  | 16.2% (9.0%; 29.0%)   | 14.5% (7.6%; 27.6%)   | 10.5% (4.4%; 25.5%)    | FU<10y                |  |
| <b>Other</b>                        | All   | 106       | 54.2% (45.3%; 64.9%)    | 48.5% (39.4%; 59.6%)  | 44.5% (35.1%; 56.3%)  | 42.5% (32.7%; 55.2%)  | 38.8% (28.7%; 52.4%)   | 36.5% (23.0%; 57.8%)  |  |
|                                     | I     | 9         | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
|                                     | II    | 20        | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
|                                     | III   | 11        | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
|                                     | IV    | 29        | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
|                                     | X/NA  | 37        | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
| <b>Females</b>                      |       |           |                         |                       |                       |                       |                        |                       |  |
| <b>Papillary carcinoma &lt;55y</b>  | All   | 3,611     | 99.8% (99.6%; 100.0%)   | 99.7% (99.5%; 99.9%)  | 99.7% (99.4%; 100.0%) | 99.5% (99.1%; 99.8%)  | 99.6% (99.2%; 99.9%)   | 99.3% (98.5%; 100.1%) |  |
|                                     | I     | 3,318     | 99.8% (99.6%; 100.0%)   | 99.7% (99.5%; 100.0%) | 99.7% (99.4%; 100.0%) | 99.6% (99.3%; 100.0%) | 99.7% (99.3%; 100.0%)  | 99.4% (98.6%; 100.2%) |  |
|                                     | II    | 71        | 98.8% (96.1%; 101.6%)   | 99.0% (96.3%; 101.8%) | 99.2% (96.5%; 102.0%) | 95.0% (89.5%; 100.8%) | 95.2% (89.8%; 101.0%)  | 97.0% (91.4%; 102.9%) |  |
|                                     | III   | 79        | 100.2% (100.2%; 100.2%) | 99.2% (96.8%; 101.7%) | 99.4% (97.0%; 101.9%) | 98.4% (95.0%; 102.0%) | 98.7% (95.2%; 102.3%)  | 97.0% (91.2%; 103.2%) |  |
|                                     | IV    | 18        | N<50                    | N<50                  | N<50                  | N<50                  | N<50                   | N<50                  |  |
|                                     | X/NA  | 125       | 99.3% (97.7%; 100.9%)   | 99.5% (97.9%; 101.1%) | 99.6% (98.0%; 101.2%) | 99.8% (98.2%; 101.4%) | 100.0% (98.4%; 101.6%) | 98.5% (94.5%; 102.6%) |  |

| Net Survival Probability, 2013-2022 |       |           |                         |                         |                         |                         |                         |                         |
|-------------------------------------|-------|-----------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Type                                | Stage | N at risk | 1-y (95%CI)             | 2-y (95%CI)             | 3-y (95%CI)             | 4-y (95%CI)             | 5-y (95%CI)             | 10-y (95%CI)            |
| <b>Papillary carcinoma 55+y</b>     | All   | 2,372     | 98.8% (98.2%; 99.5%)    | 98.8% (98.0%; 99.7%)    | 99.1% (98.1%; 100.2%)   | 99.5% (98.3%; 100.7%)   | 99.1% (97.7%; 100.6%)   | 102.4% (98.8%; 106.1%)  |
|                                     | I     | 1,674     | 100.3% (99.9%; 100.8%)  | 100.6% (99.9%; 101.3%)  | 101.6% (100.8%; 102.4%) | 102.2% (101.2%; 103.2%) | 102.4% (101.1%; 103.7%) | 107.4% (103.8%; 111.3%) |
|                                     | II    | 321       | 98.0% (95.9%; 100.2%)   | 99.0% (96.7%; 101.4%)   | 97.8% (94.7%; 101.1%)   | 97.0% (93.2%; 101.0%)   | 96.4% (92.0%; 101.0%)   | 95.1% (82.8%; 109.3%)   |
|                                     | III   | 182       | 99.3% (96.9%; 101.7%)   | 99.4% (96.1%; 102.7%)   | 100.6% (96.9%; 104.5%)  | 102.5% (98.3%; 106.9%)  | 100.8% (95.0%; 106.9%)  | 100.5% (88.6%; 113.9%)  |
|                                     | IV    | 94        | 82.4% (74.4%; 91.1%)    | 75.6% (66.3%; 86.1%)    | 69.1% (58.8%; 81.1%)    | 64.5% (53.5%; 77.7%)    | 65.9% (54.5%; 79.8%)    | 65.4% (49.8%; 85.8%)    |
|                                     | X/NA  | 101       | 91.3% (85.2%; 97.8%)    | 90.2% (83.1%; 97.8%)    | 89.0% (81.0%; 97.8%)    | 90.2% (81.7%; 99.6%)    | 84.3% (74.0%; 96.0%)    | 88.1% (70.6%; 109.8%)   |
| <b>Follicular carcinoma &lt;55y</b> | All   | 374       | 99.6% (98.8%; 100.3%)   | 99.7% (99.0%; 100.5%)   | 99.0% (97.7%; 100.2%)   | 99.1% (97.9%; 100.4%)   | 98.5% (96.9%; 100.2%)   | 97.4% (94.3%; 100.5%)   |
|                                     | I     | 288       | 99.4% (98.5%; 100.4%)   | 99.5% (98.6%; 100.5%)   | 99.3% (98.0%; 100.5%)   | 99.4% (98.2%; 100.6%)   | 99.0% (97.3%; 100.6%)   | 97.4% (93.7%; 101.2%)   |
|                                     | II    | 36        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | III   | 11        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | IV    | 4         | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | X/NA  | 35        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
| <b>Follicular carcinoma 55+y</b>    | All   | 374       | 96.1% (93.5%; 98.7%)    | 95.6% (92.4%; 98.9%)    | 95.6% (91.8%; 99.5%)    | 93.0% (88.1%; 98.3%)    | 89.5% (83.0%; 96.6%)    | 90.5% (80.0%; 102.3%)   |
|                                     | I     | 136       | 100.3% (98.2%; 102.5%)  | 101.6% (99.0%; 104.3%)  | 103.2% (100.1%; 106.5%) | 101.7% (96.3%; 107.4%)  | 98.2% (90.3%; 106.7%)   | 102.5% (85.7%; 122.7%)  |
|                                     | II    | 104       | 99.3% (95.4%; 103.2%)   | 101.0% (96.2%; 106.0%)  | 103.2% (97.3%; 109.5%)  | 99.7% (89.8%; 110.6%)   | 104.6% (94.2%; 116.1%)  | 113.6% (91.8%; 140.6%)  |
|                                     | III   | 44        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | IV    | 59        | 78.0% (67.2%; 90.4%)    | 72.3% (60.1%; 86.9%)    | 68.6% (55.4%; 85.0%)    | 62.3% (47.8%; 81.1%)    | 40.4% (22.1%; 73.8%)    | FU<10y                  |
|                                     | X/NA  | 31        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
| <b>Medullary carcinoma</b>          | All   | 203       | 97.7% (95.1%; 100.3%)   | 95.7% (92.2%; 99.3%)    | 95.2% (91.2%; 99.3%)    | 95.0% (90.5%; 99.8%)    | 95.0% (89.9%; 100.4%)   | 90.2% (78.5%; 103.7%)   |
|                                     | I     | 89        | 101.0% (101.0%; 101.0%) | 102.1% (102.1%; 102.1%) | 103.4% (103.4%; 103.4%) | 104.8% (104.8%; 104.8%) | 106.4% (106.4%; 106.4%) | 115.9% (103.1%; 130.3%) |
|                                     | II    | 31        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | III   | 20        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |
|                                     | IV    | 52        | 91.9% (84.0%; 100.5%)   | 80.6% (69.7%; 93.3%)    | 77.1% (65.3%; 91.1%)    | 74.8% (61.7%; 90.6%)    | 67.3% (52.0%; 87.0%)    | 67.9% (49.4%; 93.4%)    |
|                                     | X/NA  | 11        | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    | N<50                    |

| Net Survival Probability, 2013-2022 |       |           |                      |                      |                      |                      |                      |                      |
|-------------------------------------|-------|-----------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Type                                | Stage | N at risk | 1-y (95%CI)          | 2-y (95%CI)          | 3-y (95%CI)          | 4-y (95%CI)          | 5-y (95%CI)          | 10-y (95%CI)         |
| <b>Anaplastic carcinoma</b>         | All   | 104       | 15.9% (10.2%; 24.8%) | 10.4% (5.7%; 18.8%)  | 9.3% (4.9%; 17.6%)   | 8.2% (4.1%; 16.3%)   | 8.3% (4.2%; 16.6%)   | 8.5% (3.9%; 18.6%)   |
| <b>Other</b>                        | All   | 192       | 61.6% (54.9%; 69.1%) | 56.0% (49.0%; 63.9%) | 52.2% (45.0%; 60.6%) | 51.7% (44.3%; 60.5%) | 50.2% (42.0%; 59.9%) | 37.9% (27.0%; 53.2%) |
|                                     | I     | 37        | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 |
|                                     | II    | 19        | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 |
|                                     | III   | 3         | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 | N<50                 |
|                                     | IV    | 57        | 32.9% (22.7%; 47.8%) | 25.7% (16.3%; 40.7%) | 24.4% (15.0%; 39.8%) | 25.6% (15.7%; 41.8%) | 23.9% (13.7%; 41.4%) | FU<10y               |
|                                     | X/NA  | 76        | 60.4% (50.0%; 72.9%) | 53.6% (43.0%; 66.8%) | 46.8% (36.1%; 60.7%) | 46.2% (35.2%; 60.5%) | 43.0% (31.1%; 59.6%) | 39.3% (26.6%; 58.0%) |

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

## 5. CANCER SURVIVAL TRENDS



### 5.1. Thyroid cancer survival trends: by tumour type and tumour stage

5.1.1. Thyroid cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2008-2022

| Type                     | Period    | Stage | Males       |                          |                         |                         | Females     |                          |                         |                         |
|--------------------------|-----------|-------|-------------|--------------------------|-------------------------|-------------------------|-------------|--------------------------|-------------------------|-------------------------|
|                          |           |       | N at risk   | Net Survival Probability |                         |                         | N at risk   | Net Survival Probability |                         |                         |
|                          |           |       | 1-y (95%CI) | 3-y (95%CI)              | 5-y (95%CI)             | 1-y (95%CI)             | 3-y (95%CI) | 5-y (95%CI)              |                         |                         |
| Papillary carcinoma <55y | 2008-2012 | All   | 420         | 99.3% (98.4%; 100.2%)    | 99.4% (98.2%; 100.5%)   | 99.3% (97.9%; 100.7%)   | 1,619       | 99.8% (99.6%; 100.1%)    | 99.8% (99.4%; 100.2%)   | 99.6% (99.1%; 100.2%)   |
|                          |           | I     | 280         | 100.2% (100.2%; 100.2%)  | 100.0% (99.0%; 101.0%)  | 99.8% (98.4%; 101.2%)   | 1,229       | 99.8% (99.5%; 100.1%)    | 99.9% (99.5%; 100.3%)   | 99.9% (99.3%; 100.4%)   |
|                          |           | II    | 23          | N<50                     | N<50                    | N<50                    | 68          | 100.2% (100.2%; 100.2%)  | 100.7% (100.7%; 100.7%) | 99.8% (97.0%; 102.7%)   |
|                          |           | III   | 38          | N<50                     | N<50                    | N<50                    | 58          | 100.3% (100.3%; 100.3%)  | 99.1% (95.8%; 102.5%)   | 97.9% (93.3%; 102.8%)   |
|                          |           | IV    | 13          | N<50                     | N<50                    | N<50                    | 26          | N<50                     | N<50                    | N<50                    |
|                          |           | X/NA  | 66          | 100.3% (100.3%; 100.3%)  | 100.9% (100.9%; 100.9%) | 101.6% (101.6%; 101.6%) | 238         | 99.7% (98.9%; 100.5%)    | 99.2% (97.8%; 100.6%)   | 99.1% (97.5%; 100.8%)   |
|                          | 2013-2017 | All   | 491         | 99.6% (98.9%; 100.3%)    | 99.0% (97.9%; 100.2%)   | 98.5% (97.1%; 100.0%)   | 1,890       | 99.7% (99.5%; 100.0%)    | 99.7% (99.4%; 100.1%)   | 99.9% (99.5%; 100.3%)   |
|                          |           | I     | 392         | 99.4% (98.6%; 100.3%)    | 98.8% (97.5%; 100.1%)   | 98.5% (96.9%; 100.1%)   | 1,638       | 99.7% (99.4%; 100.0%)    | 99.7% (99.3%; 100.1%)   | 99.9% (99.5%; 100.4%)   |
|                          |           | II    | 24          | N<50                     | N<50                    | N<50                    | 63          | 98.6% (95.6%; 101.7%)    | 99.1% (96.1%; 102.2%)   | 98.0% (93.6%; 102.5%)   |
|                          |           | III   | 26          | N<50                     | N<50                    | N<50                    | 79          | 100.2% (100.2%; 100.2%)  | 99.4% (97.0%; 101.9%)   | 98.7% (95.2%; 102.2%)   |
|                          |           | IV    | 23          | N<50                     | N<50                    | N<50                    | 18          | N<50                     | N<50                    | N<50                    |
|                          |           | X/NA  | 26          | N<50                     | N<50                    | N<50                    | 92          | 100.1% (100.1%; 100.1%)  | 100.4% (100.4%; 100.4%) | 100.8% (100.8%; 100.8%) |
|                          | 2018-2022 | All   | 437         | 99.7% (99.1%; 100.4%)    | 99.9% (99.2%; 100.7%)   | 99.1% (97.4%; 100.8%)   | 1,721       | 99.8% (99.6%; 100.1%)    | 99.7% (99.2%; 100.1%)   | 98.9% (98.0%; 99.7%)    |
|                          |           | I     | 424         | 99.7% (99.1%; 100.4%)    | 100.2% (99.5%; 100.8%)  | 99.3% (97.6%; 101.0%)   | 1,680       | 99.9% (99.6%; 100.1%)    | 99.7% (99.3%; 100.1%)   | 99.1% (98.3%; 99.9%)    |

| Type                                | Period           | Stage | Males                    |                        |                        |                        | Females                  |                         |                         |                        |
|-------------------------------------|------------------|-------|--------------------------|------------------------|------------------------|------------------------|--------------------------|-------------------------|-------------------------|------------------------|
|                                     |                  |       | Net Survival Probability |                        |                        |                        | Net Survival Probability |                         |                         |                        |
|                                     |                  |       | N at risk                | 1-y (95%CI)            | 3-y (95%CI)            | 5-y (95%CI)            | N at risk                | 1-y (95%CI)             | 3-y (95%CI)             | 5-y (95%CI)            |
|                                     |                  | II    | 9                        | N<50                   | N<50                   | N<50                   | 8                        | N<50                    | N<50                    | N<50                   |
|                                     |                  | X/NA  | 4                        | N<50                   | N<50                   | N<50                   | 33                       | N<50                    | N<50                    | N<50                   |
| <b>Papillary carcinoma 55+y</b>     | <b>2008-2012</b> | All   | 369                      | 96.5% (94.1%; 99.0%)   | 93.0% (89.3%; 96.9%)   | 92.7% (88.1%; 97.5%)   | 963                      | 97.9% (96.8%; 99.2%)    | 97.8% (96.1%; 99.6%)    | 99.3% (97.1%; 101.4%)  |
|                                     |                  | I     | 148                      | 99.9% (97.6%; 102.3%)  | 100.6% (96.7%; 104.6%) | 101.9% (96.8%; 107.3%) | 525                      | 99.7% (98.7%; 100.8%)   | 100.5% (98.8%; 102.2%)  | 102.0% (99.7%; 104.2%) |
|                                     |                  | II    | 36                       | N<50                   | N<50                   | N<50                   | 92                       | 99.1% (96.2%; 102.2%)   | 98.8% (94.1%; 103.8%)   | 101.5% (96.0%; 107.3%) |
|                                     |                  | III   | 63                       | 99.1% (94.7%; 103.6%)  | 94.1% (85.7%; 103.4%)  | 96.3% (86.5%; 107.3%)  | 109                      | 97.3% (93.3%; 101.4%)   | 98.7% (93.6%; 104.2%)   | 96.2% (88.7%; 104.4%)  |
|                                     |                  | IV    | 56                       | 85.6% (75.8%; 96.6%)   | 72.1% (59.1%; 87.9%)   | 71.1% (56.4%; 89.6%)   | 75                       | 88.3% (80.4%; 97.0%)    | 81.7% (71.1%; 93.8%)    | 89.0% (77.1%; 102.6%)  |
|                                     |                  | X/NA  | 66                       | 92.9% (86.1%; 100.3%)  | 87.2% (77.8%; 97.9%)   | 79.5% (67.9%; 93.1%)   | 162                      | 96.4% (93.0%; 99.9%)    | 95.5% (90.9%; 100.3%)   | 95.6% (89.9%; 101.7%)  |
|                                     | <b>2013-2017</b> | All   | 521                      | 97.4% (95.5%; 99.3%)   | 95.2% (92.3%; 98.3%)   | 94.7% (90.9%; 98.6%)   | 1,222                    | 98.5% (97.5%; 99.5%)    | 98.8% (97.4%; 100.2%)   | 98.9% (97.0%; 100.8%)  |
| I                                   |                  | 295   | 100.3% (98.8%; 101.8%)   | 100.3% (97.3%; 103.3%) | 102.9% (99.2%; 106.9%) | 774                    | 100.0% (99.2%; 100.7%)   | 101.4% (100.2%; 102.5%) | 102.2% (100.5%; 104.0%) |                        |
| II                                  |                  | 59    | 98.8% (93.9%; 104.0%)    | 100.1% (93.1%; 107.8%) | 96.3% (85.9%; 108.0%)  | 145                    | 98.3% (95.6%; 101.2%)    | 98.6% (94.9%; 102.5%)   | 98.6% (93.7%; 103.7%)   |                        |
| III                                 |                  | 79    | 97.5% (92.7%; 102.5%)    | 91.2% (82.3%; 101.1%)  | 86.9% (76.0%; 99.5%)   | 163                    | 100.0% (97.9%; 102.2%)   | 101.5% (97.9%; 105.2%)  | 101.0% (95.2%; 107.2%)  |                        |
| IV                                  |                  | 54    | 87.7% (78.6%; 97.9%)     | 79.1% (67.0%; 93.4%)   | 71.1% (56.9%; 88.8%)   | 64                     | 87.0% (78.4%; 96.5%)     | 74.5% (62.8%; 88.5%)    | 72.2% (59.2%; 88.2%)    |                        |
| X/NA                                |                  | 34    | N<50                     | N<50                   | N<50                   | 76                     | 90.3% (83.0%; 98.1%)     | 88.1% (78.9%; 98.4%)    | 83.1% (71.8%; 96.3%)    |                        |
|                                     | <b>2018-2022</b> | All   | 524                      | 98.5% (96.8%; 100.2%)  | 96.8% (93.6%; 100.0%)  | 94.3% (89.1%; 99.8%)   | 1,150                    | 99.2% (98.4%; 100.1%)   | 99.5% (98.0%; 100.9%)   | 99.2% (96.7%; 101.7%)  |
| I                                   |                  | 355   | 99.7% (98.0%; 101.4%)    | 99.2% (95.9%; 102.7%)  | 97.7% (91.6%; 104.1%)  | 900                    | 100.7% (100.2%; 101.2%)  | 101.7% (100.6%; 102.8%) | 102.2% (100.0%; 104.5%) |                        |
| II                                  |                  | 113   | 100.3% (97.8%; 102.8%)   | 99.4% (93.9%; 105.2%)  | 99.3% (90.6%; 108.8%)  | 176                    | 97.8% (94.8%; 100.9%)    | 97.1% (92.3%; 102.3%)   | 93.2% (85.4%; 101.8%)   |                        |
| III                                 |                  | 14    | N<50                     | N<50                   | N<50                   | 19                     | N<50                     | N<50                    | N<50                    |                        |
| IV                                  |                  | 20    | N<50                     | N<50                   | N<50                   | 30                     | N<50                     | N<50                    | N<50                    |                        |
| X/NA                                |                  | 22    | N<50                     | N<50                   | N<50                   | 25                     | N<50                     | N<50                    | N<50                    |                        |
| <b>Follicular carcinoma &lt;55y</b> | <b>2008-2012</b> | All   | 63                       | 98.6% (95.6%; 101.8%)  | 99.1% (96.1%; 102.3%)  | 99.7% (96.6%; 102.8%)  | 187                      | 100.1% (100.1%; 100.1%) | 99.9% (98.8%; 100.9%)   | 98.5% (96.4%; 100.7%)  |
|                                     |                  | I     | 37                       | N<50                   | N<50                   | N<50                   | 116                      | 100.1% (100.1%; 100.1%) | 99.4% (97.7%; 101.1%)   | 98.7% (96.3%; 101.2%)  |
|                                     |                  | II    | 7                        | N<50                   | N<50                   | N<50                   | 20                       | N<50                    | N<50                    | N<50                   |

| Type                             | Period           | Stage | Males                    |                         |                         |                         | Females                  |                       |                        |                        |
|----------------------------------|------------------|-------|--------------------------|-------------------------|-------------------------|-------------------------|--------------------------|-----------------------|------------------------|------------------------|
|                                  |                  |       | Net Survival Probability |                         |                         |                         | Net Survival Probability |                       |                        |                        |
|                                  |                  |       | N at risk                | 1-y (95%CI)             | 3-y (95%CI)             | 5-y (95%CI)             | N at risk                | 1-y (95%CI)           | 3-y (95%CI)            | 5-y (95%CI)            |
|                                  |                  | III   | 5                        | N<50                    | N<50                    | N<50                    | 13                       | N<50                  | N<50                   | N<50                   |
|                                  |                  | IV    | 1                        | N<50                    | N<50                    | N<50                    | 2                        | N<50                  | N<50                   | N<50                   |
|                                  |                  | X/NA  | 13                       | N<50                    | N<50                    | N<50                    | 36                       | N<50                  | N<50                   | N<50                   |
|                                  | <b>2013-2017</b> | All   | 75                       | 100.2% (100.2%; 100.2%) | 99.4% (96.8%; 102.0%)   | 98.6% (95.0%; 102.4%)   | 206                      | 99.6% (98.7%; 100.6%) | 99.0% (97.3%; 100.6%)  | 98.3% (96.2%; 100.5%)  |
|                                  |                  | I     | 50                       | 100.2% (100.2%; 100.2%) | 98.5% (94.7%; 102.5%)   | 99.0% (95.2%; 103.0%)   | 141                      | 99.4% (98.0%; 100.8%) | 98.9% (97.0%; 100.9%)  | 98.4% (96.1%; 100.9%)  |
|                                  |                  | II    | 6                        | N<50                    | N<50                    | N<50                    | 33                       | N<50                  | N<50                   | N<50                   |
|                                  |                  | III   | 10                       | N<50                    | N<50                    | N<50                    | 11                       | N<50                  | N<50                   | N<50                   |
|                                  |                  | IV    | 1                        | N<50                    | N<50                    | N<50                    | 4                        | N<50                  | N<50                   | N<50                   |
|                                  |                  | X/NA  | 8                        | N<50                    | N<50                    | N<50                    | 17                       | N<50                  | N<50                   | N<50                   |
|                                  | <b>2018-2022</b> | All   | 58                       | 100.2% (100.2%; 100.2%) | 98.9% (95.4%; 102.5%)   | 99.5% (95.9%; 103.1%)   | 168                      | 99.5% (98.4%; 100.7%) | 98.9% (97.0%; 100.9%)  | 99.2% (97.2%; 101.2%)  |
|                                  |                  | I     | 51                       | 100.2% (100.2%; 100.2%) | 100.7% (100.7%; 100.7%) | 101.3% (101.3%; 101.3%) | 147                      | 99.4% (98.1%; 100.8%) | 99.7% (98.4%; 101.0%)  | 100.0% (98.6%; 101.3%) |
|                                  |                  | II    | 1                        | N<50                    | N<50                    | N<50                    | 3                        | N<50                  | N<50                   | N<50                   |
|                                  |                  | X/NA  | 6                        | N<50                    | N<50                    | N<50                    | 18                       | N<50                  | N<50                   | N<50                   |
| <b>Follicular carcinoma 55+y</b> | <b>2008-2012</b> | All   | 100                      | 101.6% (98.8%; 104.6%)  | 98.0% (90.8%; 105.9%)   | 93.3% (83.0%; 105.0%)   | 164                      | 95.8% (91.9%; 99.8%)  | 91.9% (85.7%; 98.7%)   | 89.5% (81.9%; 97.9%)   |
|                                  |                  | I     | 6                        | N<50                    | N<50                    | N<50                    | 33                       | N<50                  | N<50                   | N<50                   |
|                                  |                  | II    | 14                       | N<50                    | N<50                    | N<50                    | 34                       | N<50                  | N<50                   | N<50                   |
|                                  |                  | III   | 43                       | N<50                    | N<50                    | N<50                    | 38                       | N<50                  | N<50                   | N<50                   |
|                                  |                  | IV    | 23                       | N<50                    | N<50                    | N<50                    | 34                       | N<50                  | N<50                   | N<50                   |
|                                  |                  | X/NA  | 14                       | N<50                    | N<50                    | N<50                    | 25                       | N<50                  | N<50                   | N<50                   |
|                                  | <b>2013-2017</b> | All   | 112                      | 97.2% (92.6%; 101.9%)   | 90.7% (82.2%; 99.9%)    | 91.3% (81.1%; 102.7%)   | 193                      | 97.3% (94.1%; 100.5%) | 94.3% (89.2%; 99.8%)   | 85.2% (77.1%; 94.2%)   |
|                                  |                  | I     | 16                       | N<50                    | N<50                    | N<50                    | 43                       | N<50                  | N<50                   | N<50                   |
|                                  |                  | II    | 32                       | N<50                    | N<50                    | N<50                    | 57                       | 99.1% (94.4%; 104.1%) | 102.6% (95.7%; 109.9%) | 104.9% (93.9%; 117.2%) |
|                                  |                  | III   | 28                       | N<50                    | N<50                    | N<50                    | 41                       | N<50                  | N<50                   | N<50                   |

| Type                       | Period           | Stage | Males                    |                        |                        |                        | Females                  |                         |                         |                         |
|----------------------------|------------------|-------|--------------------------|------------------------|------------------------|------------------------|--------------------------|-------------------------|-------------------------|-------------------------|
|                            |                  |       | Net Survival Probability |                        |                        |                        | Net Survival Probability |                         |                         |                         |
|                            |                  |       | N at risk                | 1-y (95%CI)            | 3-y (95%CI)            | 5-y (95%CI)            | N at risk                | 1-y (95%CI)             | 3-y (95%CI)             | 5-y (95%CI)             |
|                            |                  | IV    | 22                       | N<50                   | N<50                   | N<50                   | 32                       | N<50                    | N<50                    | N<50                    |
|                            |                  | X/NA  | 14                       | N<50                   | N<50                   | N<50                   | 20                       | N<50                    | N<50                    | N<50                    |
|                            | <b>2018-2022</b> | All   | 144                      | 97.9% (94.4%; 101.7%)  | 97.5% (91.6%; 103.8%)  | 97.9% (89.4%; 107.1%)  | 181                      | 94.8% (90.8%; 99.0%)    | 97.3% (92.0%; 102.9%)   | 100.2% (91.7%; 109.5%)  |
|                            |                  | I     | 59                       | 97.0% (91.4%; 103.0%)  | 94.9% (86.3%; 104.3%)  | 100.2% (91.2%; 110.2%) | 93                       | 100.7% (98.4%; 103.1%)  | 104.3% (101.1%; 107.7%) | 108.8% (103.6%; 114.3%) |
|                            |                  | II    | 58                       | 99.4% (94.7%; 104.4%)  | 101.4% (93.9%; 109.6%) | 96.9% (82.5%; 113.7%)  | 47                       | N<50                    | N<50                    | N<50                    |
|                            |                  | III   | 2                        | N<50                   | N<50                   | N<50                   | 3                        | N<50                    | N<50                    | N<50                    |
|                            |                  | IV    | 15                       | N<50                   | N<50                   | N<50                   | 27                       | N<50                    | N<50                    | N<50                    |
|                            |                  | X/NA  | 10                       | N<50                   | N<50                   | N<50                   | 11                       | N<50                    | N<50                    | N<50                    |
| <b>Medullary carcinoma</b> | <b>2008-2012</b> | All   | 92                       | 96.5% (91.9%; 101.3%)  | 94.1% (87.2%; 101.6%)  | 86.2% (75.9%; 97.9%)   | 116                      | 92.4% (87.4%; 97.7%)    | 91.3% (85.3%; 97.6%)    | 93.4% (87.1%; 100.2%)   |
|                            |                  | I     | 20                       | N<50                   | N<50                   | N<50                   | 47                       | N<50                    | N<50                    | N<50                    |
|                            |                  | II    | 13                       | N<50                   | N<50                   | N<50                   | 19                       | N<50                    | N<50                    | N<50                    |
|                            |                  | III   | 12                       | N<50                   | N<50                   | N<50                   | 11                       | N<50                    | N<50                    | N<50                    |
|                            |                  | IV    | 34                       | N<50                   | N<50                   | N<50                   | 18                       | N<50                    | N<50                    | N<50                    |
|                            |                  | X/NA  | 13                       | N<50                   | N<50                   | N<50                   | 21                       | N<50                    | N<50                    | N<50                    |
|                            | <b>2013-2017</b> | All   | 64                       | 94.1% (87.5%; 101.2%)  | 83.6% (73.1%; 95.6%)   | 78.8% (63.5%; 97.8%)   | 92                       | 98.0% (94.3%; 101.8%)   | 92.6% (86.2%; 99.6%)    | 92.2% (84.7%; 100.4%)   |
|                            |                  | I     | 13                       | N<50                   | N<50                   | N<50                   | 36                       | N<50                    | N<50                    | N<50                    |
|                            |                  | II    | 9                        | N<50                   | N<50                   | N<50                   | 17                       | N<50                    | N<50                    | N<50                    |
|                            |                  | III   | 9                        | N<50                   | N<50                   | N<50                   | 8                        | N<50                    | N<50                    | N<50                    |
|                            |                  | IV    | 30                       | N<50                   | N<50                   | N<50                   | 22                       | N<50                    | N<50                    | N<50                    |
|                            |                  | X/NA  | 3                        | N<50                   | N<50                   | N<50                   | 9                        | N<50                    | N<50                    | N<50                    |
|                            | <b>2018-2022</b> | All   | 74                       | 100.5% (97.8%; 103.2%) | 94.8% (87.0%; 103.2%)  | 95.2% (85.5%; 105.9%)  | 111                      | 97.4% (93.9%; 101.1%)   | 97.7% (93.3%; 102.3%)   | 96.6% (88.1%; 106.0%)   |
|                            |                  | I     | 19                       | N<50                   | N<50                   | N<50                   | 53                       | 101.1% (101.1%; 101.1%) | 103.3% (103.3%; 103.3%) | 105.9% (105.9%; 105.9%) |
|                            |                  | II    | 15                       | N<50                   | N<50                   | N<50                   | 14                       | N<50                    | N<50                    | N<50                    |

| Type                        | Period           | Stage | Males                    |                      |                      |                      | Females                  |                      |                      |                      |
|-----------------------------|------------------|-------|--------------------------|----------------------|----------------------|----------------------|--------------------------|----------------------|----------------------|----------------------|
|                             |                  |       | Net Survival Probability |                      |                      |                      | Net Survival Probability |                      |                      |                      |
|                             |                  |       | N at risk                | 1-y (95%CI)          | 3-y (95%CI)          | 5-y (95%CI)          | N at risk                | 1-y (95%CI)          | 3-y (95%CI)          | 5-y (95%CI)          |
|                             |                  | III   | 12                       | N<50                 | N<50                 | N<50                 | 12                       | N<50                 | N<50                 | N<50                 |
|                             |                  | IV    | 27                       | N<50                 | N<50                 | N<50                 | 30                       | N<50                 | N<50                 | N<50                 |
|                             |                  | X/NA  | 1                        | N<50                 | N<50                 | N<50                 | 2                        | N<50                 | N<50                 | N<50                 |
| <b>Anaplastic carcinoma</b> | <b>2008-2012</b> | All   | 54                       | 17.0% (9.5%; 30.5%)  | 13.9% (7.1%; 27.1%)  | 10.4% (4.7%; 23.2%)  | 63                       | 11.8% (6.1%; 23.0%)  | 10.2% (4.7%; 22.4%)  | 5.6% (1.7%; 18.4%)   |
|                             | <b>2013-2017</b> | All   | 32                       | N<50                 | N<50                 | N<50                 | 44                       | N<50                 | N<50                 | N<50                 |
|                             | <b>2018-2022</b> | All   | 47                       | N<50                 | N<50                 | N<50                 | 60                       | 17.3% (10.0%; 29.9%) | 9.8% (4.5%; 21.7%)   | 8.0% (3.3%; 19.4%)   |
| <b>Other</b>                | <b>2008-2012</b> | All   | 45                       | N<50                 | N<50                 | N<50                 | 72                       | 63.1% (52.8%; 75.4%) | 54.3% (43.6%; 67.5%) | 49.3% (38.5%; 63.1%) |
|                             |                  | I     | 6                        | N<50                 | N<50                 | N<50                 | 13                       | N<50                 | N<50                 | N<50                 |
|                             |                  | II    | 1                        | N<50                 | N<50                 | N<50                 | 1                        | N<50                 | N<50                 | N<50                 |
|                             |                  | III   | 5                        | N<50                 | N<50                 | N<50                 | 6                        | N<50                 | N<50                 | N<50                 |
|                             |                  | IV    | 13                       | N<50                 | N<50                 | N<50                 | 19                       | N<50                 | N<50                 | N<50                 |
|                             |                  | X/NA  | 20                       | N<50                 | N<50                 | N<50                 | 33                       | N<50                 | N<50                 | N<50                 |
|                             | <b>2013-2017</b> | All   | 50                       | 47.2% (35.1%; 63.6%) | 38.9% (26.9%; 56.4%) | 37.0% (24.5%; 55.8%) | 91                       | 54.7% (45.3%; 66.2%) | 42.0% (32.7%; 54.1%) | 42.3% (32.2%; 55.6%) |
|                             |                  | I     | 1                        | N<50                 | N<50                 | N<50                 | 8                        | N<50                 | N<50                 | N<50                 |
|                             |                  | II    | 4                        | N<50                 | N<50                 | N<50                 | 8                        | N<50                 | N<50                 | N<50                 |
|                             |                  | III   | 7                        | N<50                 | N<50                 | N<50                 | 2                        | N<50                 | N<50                 | N<50                 |
|                             |                  | IV    | 14                       | N<50                 | N<50                 | N<50                 | 29                       | N<50                 | N<50                 | N<50                 |
|                             |                  | X/NA  | 24                       | N<50                 | N<50                 | N<50                 | 44                       | N<50                 | N<50                 | N<50                 |
|                             | <b>2018-2022</b> | All   | 56                       | 60.5% (48.7%; 75.1%) | 49.9% (37.2%; 66.9%) | 32.1% (17.3%; 59.6%) | 101                      | 67.8% (58.9%; 78.0%) | 62.2% (52.3%; 74.0%) | 56.2% (44.2%; 71.3%) |
|                             |                  | I     | 8                        | N<50                 | N<50                 | N<50                 | 29                       | N<50                 | N<50                 | N<50                 |
|                             |                  | II    | 16                       | N<50                 | N<50                 | N<50                 | 11                       | N<50                 | N<50                 | N<50                 |
|                             |                  | III   | 4                        | N<50                 | N<50                 | N<50                 | 1                        | N<50                 | N<50                 | N<50                 |
|                             |                  | IV    | 15                       | N<50                 | N<50                 | N<50                 | 28                       | N<50                 | N<50                 | N<50                 |



| Type | Period | Stage | Males                    |             |             |             | Females                  |             |             |             |
|------|--------|-------|--------------------------|-------------|-------------|-------------|--------------------------|-------------|-------------|-------------|
|      |        |       | Net Survival Probability |             |             |             | Net Survival Probability |             |             |             |
|      |        |       | N at risk                | 1-y (95%CI) | 3-y (95%CI) | 5-y (95%CI) | N at risk                | 1-y (95%CI) | 3-y (95%CI) | 5-y (95%CI) |
|      |        | X/NA  | 13                       | N<50        | N<50        | N<50        | 32                       | N<50        | N<50        | N<50        |

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

## 6. CANCER MORTALITY



### 6.1. Thyroid cancer mortality: by region

6.1.1. Thyroid cancer mortality\* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

| Region         | N [CR] |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |        |        | ESR2013 (95%CI) |            |
|----------------|--------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|--------|-----------------|------------|
|                | 0-     | 5-    | 10-   | 15-   | 20-   | 25-   | 30-   | 35-   | 40-   | 45-   | 50-   | 55-   | 60-   | 65-   | 70-   | 75-   | 80-   | 85-   | 90-    | 95-    |                 | All ages   |
| Males          |        |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |        |        |                 |            |
| <b>Belgium</b> | 0      | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 1     | 0     | 3     | 4     | 6     | 5     | 7     | 5     | 3      | 1      | 35              | 0.7        |
|                | [0.0]  | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.3] | [0.0] | [0.8] | [1.3] | [2.3] | [2.9] | [5.4] | [6.4] | [10.7] | [18.3] | [0.6]           | (0.5; 1.0) |
| Brussels       | 0      | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 1     | 0     | 0     | 0     | 1      | 0      | 2               | 0.7        |
|                | [0.0]  | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [6.0] | [0.0] | [0.0] | [0.0] | [46.0] | [0.0]  | [0.3]           | (0.0; 1.6) |
| Flanders       | 0      | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 1     | 0     | 1     | 3     | 2     | 4     | 5     | 3     | 2      | 0      | 21              | 0.7        |
|                | [0.0]  | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.4] | [0.0] | [0.5] | [1.6] | [1.2] | [3.5] | [5.8] | [5.8] | [10.9] | [0.0]  | [0.6]           | (0.4; 1.0) |
| Wallonia       | 0      | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 2     | 1     | 3     | 1     | 2     | 2     | 0      | 1      | 12              | 0.8        |
|                | [0.0]  | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [1.7] | [1.0] | [3.5] | [2.1] | [5.6] | [9.6] | [0.0]  | [71.1] | [0.7]           | (0.3; 1.3) |
| Females        |        |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |        |        |                 |            |
| <b>Belgium</b> | 0      | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 1     | 2     | 1     | 8     | 9     | 4     | 4     | 5      | 1      | 35              | 0.5        |
|                | [0.0]  | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.2] | [0.5] | [0.3] | [2.7] | [4.2] | [2.2] | [3.0] | [7.5]  | [5.2]  | [0.6]           | (0.4; 0.7) |
| Brussels       | 0      | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 1     | 0     | 0     | 0     | 0     | 0     | 1      | 0      | 2               | 0.3        |
|                | [0.0]  | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [3.4] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [17.4] | [0.0]  | [0.3]           | (0.0; 0.8) |

| Region   | N [CR] |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       | ESR2013 (95%CI) |            |
|----------|--------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----------------|------------|
|          | 0-     | 5-    | 10-   | 15-   | 20-   | 25-   | 30-   | 35-   | 40-   | 45-   | 50-   | 55-   | 60-   | 65-   | 70-   | 75-   | 80-   | 85-   | 90-   | 95-   |                 | All ages   |
| Flanders | 0      | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 1     | 1     | 1     | 6     | 5     | 4     | 4     | 2     | 1     | 25              | 0.6        |
|          | [0.0]  | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.4] | [0.5] | [0.5] | [3.4] | [3.8] | [3.4] | [4.7] | [5.0] | [8.9] | [0.7]           | (0.4; 0.9) |
| Wallonia | 0      | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 2     | 4     | 0     | 0     | 2     | 0     | 8               | 0.4        |
|          | [0.0]  | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [0.0] | [2.0] | [6.3] | [0.0] | [0.0] | [9.8] | [0.0] | [0.4]           | (0.1; 0.7) |

## 7. CANCER MORTALITY TRENDS



### 7.1. Thyroid cancer mortality trends: by region

7.1.1. Thyroid cancer mortality\* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

| Region   |                | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | AAPC, % (95%CI) | Period           |
|----------|----------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-----------------|------------------|
| Belgium  | <b>N</b>       | 28   | 25   | 26   | 25   | 33   | 33   | 33   | 35   | 40   | 33   | 17   | 29   | 30   | 25   | 37   | 33   | 19   | 35   |                 |                  |
|          | <b>CR</b>      | 0.6  | 0.5  | 0.5  | 0.5  | 0.6  | 0.6  | 0.6  | 0.7  | 0.7  | 0.6  | 0.3  | 0.5  | 0.5  | 0.4  | 0.7  | 0.6  | 0.3  | 0.6  |                 |                  |
|          | <b>ESR2013</b> | 0.7  | 0.7  | 0.6  | 0.6  | 0.8  | 0.7  | 0.8  | 0.8  | 0.8  | 0.9  | 0.8  | 0.4  | 0.6  | 0.7  | 0.5  | 0.8  | 0.6  | 0.4  | 0.7             | -1.2 (-3.6; 1.2) |
| Brussels | <b>N</b>       | 3    | 0    | 1    | 1    | 1    | 2    | 4    | 1    | 2    | 1    | 1    | 2    | 3    | 3    | 3    | 2    | 3    | 2    |                 |                  |
|          | <b>CR</b>      | 0.6  | 0.0  | 0.2  | 0.2  | 0.2  | 0.4  | 0.8  | 0.2  | 0.4  | 0.2  | 0.2  | 0.3  | 0.5  | 0.5  | 0.5  | 0.3  | 0.5  | 0.3  |                 |                  |
|          | <b>ESR2013</b> | 0.9  | 0.0  | 0.3  | 0.3  | 0.3  | 0.6  | 1.1  | 0.2  | 0.5  | 0.2  | 0.3  | 0.5  | 0.9  | 0.9  | 0.8  | 0.6  | 0.8  | 0.7  |                 | 2004-2021        |
| Flanders | <b>N</b>       | 16   | 19   | 16   | 17   | 20   | 25   | 15   | 25   | 26   | 24   | 11   | 21   | 20   | 12   | 22   | 19   | 13   | 21   |                 |                  |
|          | <b>CR</b>      | 0.5  | 0.6  | 0.5  | 0.6  | 0.7  | 0.8  | 0.5  | 0.8  | 0.8  | 0.8  | 0.3  | 0.7  | 0.6  | 0.4  | 0.7  | 0.6  | 0.4  | 0.6  |                 |                  |
|          | <b>ESR2013</b> | 0.7  | 0.8  | 0.6  | 0.7  | 0.8  | 0.9  | 0.6  | 1.0  | 1.0  | 0.9  | 0.4  | 0.7  | 0.8  | 0.4  | 0.7  | 0.6  | 0.4  | 0.7  |                 | -1.8 (-4.5; 0.9) |
| Wallonia | <b>N</b>       | 9    | 6    | 9    | 7    | 12   | 6    | 14   | 9    | 12   | 8    | 5    | 6    | 7    | 10   | 12   | 12   | 3    | 12   |                 |                  |
|          | <b>CR</b>      | 0.5  | 0.4  | 0.5  | 0.4  | 0.7  | 0.4  | 0.8  | 0.5  | 0.7  | 0.5  | 0.3  | 0.3  | 0.4  | 0.6  | 0.7  | 0.7  | 0.2  | 0.7  |                 |                  |
|          | <b>ESR2013</b> | 0.7  | 0.6  | 0.6  | 0.5  | 0.9  | 0.4  | 1.0  | 0.6  | 0.9  | 0.6  | 0.3  | 0.5  | 0.5  | 0.7  | 0.8  | 0.8  | 0.2  | 0.8  |                 | -1.7 (-5.9; 2.7) |

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Thyroid cancer mortality\* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

| Region   |                | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | AAPC, % (95%CI)   | Period    |
|----------|----------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-------------------|-----------|
| Belgium  | <b>N</b>       | 48   | 51   | 45   | 43   | 46   | 51   | 47   | 54   | 54   | 41   | 51   | 46   | 37   | 29   | 52   | 41   | 46   | 35   |                   |           |
|          | <b>CR</b>      | 0.9  | 1.0  | 0.8  | 0.8  | 0.8  | 0.9  | 0.9  | 1.0  | 1.0  | 0.7  | 0.9  | 0.8  | 0.6  | 0.5  | 0.9  | 0.7  | 0.8  | 0.6  |                   |           |
|          | <b>ESR2013</b> | 0.9  | 0.9  | 0.8  | 0.7  | 0.8  | 0.9  | 0.8  | 1.0  | 0.9  | 0.7  | 0.8  | 0.8  | 0.6  | 0.5  | 0.8  | 0.6  | 0.7  | 0.5  | -2.6 (-4.1; -1.2) | 2004-2021 |
| Brussels | <b>N</b>       | 4    | 4    | 8    | 2    | 3    | 4    | 1    | 5    | 5    | 3    | 3    | 4    | 2    | 2    | 1    | 3    | 4    | 2    |                   |           |
|          | <b>CR</b>      | 0.8  | 0.8  | 1.5  | 0.4  | 0.6  | 0.7  | 0.2  | 0.9  | 0.9  | 0.5  | 0.5  | 0.7  | 0.3  | 0.3  | 0.2  | 0.5  | 0.6  | 0.3  |                   |           |
|          | <b>ESR2013</b> | 0.7  | 0.7  | 1.9  | 0.4  | 0.6  | 0.8  | 0.2  | 0.9  | 1.2  | 0.7  | 0.5  | 0.9  | 0.4  | 0.3  | 0.1  | 0.5  | 0.7  | 0.3  | -4.9 (-10.0; 0.5) | 2004-2021 |
| Flanders | <b>N</b>       | 27   | 34   | 20   | 27   | 35   | 31   | 26   | 36   | 37   | 23   | 39   | 30   | 24   | 20   | 37   | 28   | 32   | 25   |                   |           |
|          | <b>CR</b>      | 0.9  | 1.1  | 0.6  | 0.9  | 1.1  | 1.0  | 0.8  | 1.1  | 1.2  | 0.7  | 1.2  | 0.9  | 0.7  | 0.6  | 1.1  | 0.8  | 1.0  | 0.7  |                   |           |
|          | <b>ESR2013</b> | 0.9  | 1.1  | 0.6  | 0.8  | 1.0  | 0.9  | 0.7  | 1.1  | 1.0  | 0.6  | 1.0  | 0.8  | 0.6  | 0.5  | 0.9  | 0.7  | 0.7  | 0.6  | -1.8 (-3.8; 0.2)  | 2004-2021 |
| Wallonia | <b>N</b>       | 17   | 13   | 17   | 14   | 8    | 16   | 20   | 13   | 12   | 15   | 9    | 12   | 11   | 7    | 14   | 10   | 10   | 8    |                   |           |
|          | <b>CR</b>      | 1.0  | 0.7  | 1.0  | 0.8  | 0.4  | 0.9  | 1.1  | 0.7  | 0.7  | 0.8  | 0.5  | 0.7  | 0.6  | 0.4  | 0.8  | 0.5  | 0.5  | 0.4  |                   |           |
|          | <b>ESR2013</b> | 0.9  | 0.7  | 1.0  | 0.8  | 0.4  | 1.0  | 1.0  | 0.7  | 0.6  | 0.8  | 0.4  | 0.6  | 0.5  | 0.3  | 0.7  | 0.4  | 0.5  | 0.4  | -3.9 (-6.4; -1.4) | 2004-2021 |

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

\*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2025